
From: Rohrbaugh, Mark (NIH/OD) [E] [/O=NIH/OU=NIH/EXCHANGE/CN=OD/CN=ROHRBAUM]
Sent: 11/1/2016 2:05:45 PM
To: Fine, Amanda (NIH/OD) [E] [/O=NIH/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=Fineab]
Subject: Re: Interview request/chlorcyclizine pricing: BuzzFeed News

I don't know where that data would be if we have it. It's 20 yrs old. The data on the website goes back to 2003.

Sent from my iPhone

On Nov 1, 2016, at 9:48 AM, Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov> wrote:

Hi Mark-

Was hoping we could pin down a time for you to speak with Dan today if you are available. Also, he asked if we have the numbers behind the CRADA increases from 1980 to present—they are thinking they would like to make a chart to show the difference in collaborations pre/post reasonable pricing clause.

Thanks!
Amanda

From: Fine, Amanda (NIH/OD) [E]
Sent: Monday, October 31, 2016 2:00 PM
To: Rohrbaugh, Mark (NIH/OD) [E] <RohrBauM@OD.NIH.GOV>
Cc: Myles, Renate (NIH/OD) [E] <mylesr@od.nih.gov>; Wojtowicz, Emma (NIH/OD) [E] <emma.wojtowicz@nih.gov>
Subject: RE: Interview request/chlorcyclizine pricing: BuzzFeed News

Hi Mark-

Wasn't sure if you saw my below email. Is there a time tomorrow that would work for you to speak with Dan?

Thanks again!
Amanda

From: Fine, Amanda (NIH/OD) [E]
Sent: Monday, October 31, 2016 9:55 AM
To: Rohrbaugh, Mark (NIH/OD) [E] <RohrBauM@OD.NIH.GOV>
Cc: Myles, Renate (NIH/OD) [E] <mylesr@od.nih.gov>; Wojtowicz, Emma (NIH/OD) [E] <emma.wojtowicz@nih.gov>
Subject: FW: Interview request/chlorcyclizine pricing: BuzzFeed News

Good morning and welcome back!

I wanted to check in to see what your availability is to speak to Dan either later today or sometime tomorrow. We're hoping to provide him with the background information prior to speaking with you.

Thanks!

Amanda

From: Fine, Amanda (NIH/OD) [E]
Sent: Friday, October 28, 2016 6:11 PM
To: Ano, Susan (NIH/NINDS) [E] <susan.ano@nih.gov>
Cc: Rodriguez, Richard (NIH/NCI) [E] <richard.rodriguez@nih.gov>; Chang, Kevin (NIH/NCI) [E] <changke@mail.nih.gov>; Myles, Renate (NIH/OD) [E] <mylesr@od.nih.gov>; Wojtowicz, Emma (NIH/OD) [E] <emma.wojtowicz@nih.gov>; NCI Press Officers <ncipressofficers@mail.nih.gov>; Rohrbaugh, Mark (NIH/OD) [E] <RohrBauM@OD.NIH.GOV>; Niebylski, Charles (NIH/NIDDK) [E] <niebylskicd@niddk.nih.gov>
Subject: Re: Interview request/chlorcyclizine pricing: BuzzFeed News

Hi All-

Sorry for the delay. For your review and input, please see the below draft response:

(b) (5)

REL0000024708

Thanks!

Amanda

On Oct 28, 2016, at 11:24 AM, Ano, Susan (NIH/NINDS) [E] <susan.ano@nih.gov> wrote:

There's a typo in the email below. The first statement should read

(b) (5)

(b) (5)

Best regards,

Sue

Susan Ano, Ph.D.
Technology Development Coordinator
Office of Technology Transfer
The National Institute of Neurological Disorders and Stroke
The National Institutes of Health
Mail address: 31 Center Drive, Suite 8A52, MS2540
Bethesda, MD 20892
Physical location: Bldg. 31, 8A07
phone (301) 435-5515
cell (b) (6)

<image001.jpg>

Have patience. All things are difficult before they become easy."

— Saadi, poet

The attached information may be confidential. It is intended only for the addressee(s) identified above. If you are not the addressee(s), or an employee or agent of the addressee(s), please note that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this email in error, please destroy the document and notify the sender of the error. Thank you.

From: Rodriguez, Richard (NIH/NCI) [E]
Sent: Friday, October 28, 2016 11:12 AM
To: Chang, Kevin (NIH/NCI) [E] <changke@mail.nih.gov>
Cc: Myles, Renate (NIH/OD) [E] <mylesr@od.nih.gov>; Wojtowicz, Emma (NIH/OD) [E] <emma.wojtowicz@nih.gov>; NCI Press Officers <ncipressofficers@mail.nih.gov>; Rohrbaugh, Mark (NIH/OD) [E] <RohrBauM@OD.NIH.GOV>; Niebylski, Charles (NIH/NIDDK) [E] <niebylskicd@niddk.nih.gov>; Ano, Susan (NIH/NINDS) [E] <susan.ano@nih.gov>; Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>
Subject: RE: Interview request/chlorcyclizine pricing: BuzzFeed News

(b) (5)

Richard

From: Chang, Kevin (NIH/NCI) [E]
Sent: Friday, October 28, 2016 11:08 AM
To: Rodriguez, Richard (NIH/NCI) [E] <richard.rodriguez@nih.gov>; Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>
Cc: Myles, Renate (NIH/OD) [E] <mylesr@od.nih.gov>; Wojtowicz, Emma (NIH/OD) [E] <emma.wojtowicz@nih.gov>; NCI Press Officers <ncipressofficers@mail.nih.gov>; Rohrbaugh, Mark (NIH/OD) [E] <RohrBauM@OD.NIH.GOV>; Niebylski, Charles (NIH/NIDDK) [E] <niebylskicd@niddk.nih.gov>; Ano, Susan (NIH/NINDS) [E] <susan.ano@nih.gov>
Subject: RE: Interview request/chlorcyclizine pricing: BuzzFeed News

Hi Richard,

(b) (5)

Sue was working on responses to the questions.

Kevin W. Chang, Ph.D.
Senior Licensing and Patenting Manager
NCI Technology Transfer Center
9609 Medical Center Dr.
Room 3W-128, MSC 9702
Rockville, MD 20850-9702
Phone: 240-276-6910
Email: changke@mail.nih.gov

REL0000024708

The attached information may be confidential. It is intended only for the addressee(s) identified above. If you are not the addressee(s), or an employee or agent of the addressee(s), please note that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this email in error, please destroy the document and notify the sender of the error. Thank you.

From: Rodriguez, Richard (NIH/NCI) [E]
Sent: Friday, October 28, 2016 11:04 AM
To: Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>
Cc: Myles, Renate (NIH/OD) [E] <mylesr@od.nih.gov>; Wojtowicz, Emma (NIH/OD) [E] <emma.wojtowicz@nih.gov>; NCI Press Officers <ncipressofficers@mail.nih.gov>; Rohrbaugh, Mark (NIH/OD) [E] <RohrBauM@OD.NIH.GOV>; Niebylski, Charles (NIH/NIDDK) [E] <niebylskicd@nidk.nih.gov>; Ano, Susan (NIH/NINDS) [E] <susan.ano@nih.gov>; Chang, Kevin (NIH/NCI) [E] <changke@mail.nih.gov>
Subject: RE: Interview request/chlorcyclizine pricing: BuzzFeed News

Hi Amanda,

Just saw this and have attached my response to Chuck. If you have more questions, I'm happy to have a call.

Thanks,

Richard

RICHARD U. RODRIGUEZ, M.B.A.

Associate Director, Technology Transfer Center
Patent Agent

National Cancer Institute
National Institutes of Health
9609 Medical Center Drive, Rm 1E530
Bethesda, MD 20892-9702 (for business mail)
Rockville, MD 20850-9702 (for courier service/visitors)
Phone (Main Office): 240-276-5530
Direct phone: 240-276-6661
Fax 240-276-5504
richard.rodriquez@nih.gov

<https://ttc.nci.nih.gov/index.php>

"Change is inevitable. Progress is optional" – Tony Roberts

Note: This email may contain confidential information. If you are not the intended recipient, any disclosure, copying or use of this email or the information enclosed therein is strictly prohibited, and you should notify the sender for return of any attached documents.

From: Chang, Kevin (NIH/NCI) [E]
Sent: Thursday, October 27, 2016 6:26 PM

REL0000024708

To: Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>
Cc: Myles, Renate (NIH/OD) [E] <mylesr@od.nih.gov>; Wojtowicz, Emma (NIH/OD) [E] <emma.wojtowicz@nih.gov>; NCI Press Officers <ncipressofficers@mail.nih.gov>; Rohrbaugh, Mark (NIH/OD) [E] <RohrBauM@OD.NIH.GOV>; Niebylski, Charles (NIH/NIDDK) [E] <niebylskicd@niddk.nih.gov>; Rodriguez, Richard (NIH/NCI) [E] <richard.rodriguez@nih.gov>; Ano, Susan (NIH/NINDS) [E] <susan.ano@nih.gov>
Subject: RE: Interview request/chlorcyclizine pricing: BuzzFeed News
Importance: High

Hi Amanda,

Chuck has also approached me regarding these questions. Richard, Sue, and Mark may be the best positioned to provide NIH's official responses on these two questions. Richard should be back from travel on Monday but I can chat with Mark if he needs background about this specific license.

When do you need the responses to the questions by?

Best regards,

Kevin

Kevin W. Chang, Ph.D.
Senior Licensing and Patenting Manager
NCI Technology Transfer Center
9609 Medical Center Dr.
Room 3W-128, MSC 9702
Rockville, MD 20850-9702
Phone: 240-276-6910
Email: changke@mail.nih.gov

The attached information may be confidential. It is intended only for the addressee(s) identified above. If you are not the addressee(s), or an employee or agent of the addressee(s), please note that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this email in error, please destroy the document and notify the sender of the error. Thank you.

From: Fine, Amanda (NIH/OD) [E]
Sent: Thursday, October 27, 2016 5:03 PM
To: Chang, Kevin (NIH/NCI) [E] <changke@mail.nih.gov>
Cc: Myles, Renate (NIH/OD) [E] <mylesr@od.nih.gov>; Wojtowicz, Emma (NIH/OD) [E] <emma.wojtowicz@nih.gov>; NCI Press Officers <ncipressofficers@mail.nih.gov>; Rohrbaugh, Mark (NIH/OD) [E] <RohrBauM@OD.NIH.GOV>
Subject: FW: Interview request/chlorcyclizine pricing: BuzzFeed News

Hi Kevin-

Please see the below long thread about a Buzzfeed inquiry regarding chlorcyclizine as a result of a complaint by Knowledge Ecology International. As you may know, KEI regularly approaches NIH regarding licensing and exercising march-in rights. We are working to set up an interview with Mark next week, however wanted to provide the

reporter with some background. He asked a few questions about granting the license that folks said you would know and I was hoping you would help us in drafting responses to these questions. Specifically the following 2 questions:

2) What are the institute's priorities when licensing these drugs?

(b) (5)

(5) Some observers are asking: why grant an exclusive license to a small, unknown company with no track record of bringing drugs to market?

Please let me know if you have any questions.

Thank you in advance for your help and input!
Amanda

Amanda Fine
Deputy, News Media Branch
National Institutes of Health
Tel: 301-496-7246
Email: amanda.fine@nih.gov
Web: <http://www.nih.gov>

NIH . . . Turning Discovery Into Health

From: Fine, Amanda (NIH/OD) [E]
Sent: Thursday, October 27, 2016 3:42 PM
To: Kassilke, Deborah (NIH/OD) [E] <deborah.kassilke@nih.gov>; Rohrbaugh, Mark (NIH/OD) [E] <RohrBauM@OD.NIH.GOV>; Rogers, Karen (NIH/OD) [E] <RogersK@od.nih.gov>
Cc: charles.nybeliski@nih.gov; Niebylski, Charles (NIH/NIDDK) [E] <niebylskicd@niddk.nih.gov>
Subject: RE: Interview request/chlorcyclizine pricing: BuzzFeed News

Hi All-

Just following up on this to see if there was any progress in drafting responses to Dan's questions. His deadline is tomorrow.

(b) (5)

(b) (5)



(2) What are the institute's priorities when licensing these drugs?

(b) (5)



(3) How much progress has this licensee made on marketing this drug?

You would need to check with the licensee.

(4) What were the results of the Phase 1 trial that NIH funded on this drug?

These will be published in the near future.

(5) Some observers are asking: why grant an exclusive license to a small, unknown company with no track record of bringing drugs to market?

Chuck-were you able to speak to Kevin Chang about this?

Thanks to all in advance for your input and guidance.

Best,
Amanda

(b) (5)



From: Kassilke, Deborah (NIH/OD) [E]
Sent: Tuesday, October 25, 2016 11:34 AM
To: Rohrbaugh, Mark (NIH/OD) [E] <RohrBauM@OD.NIH.GOV>; Rogers, Karen (NIH/OD) [E] <RogersK@od.nih.gov>
Cc: Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>; charles.nybeliski@nih.gov;
Niebylski, Charles (NIH/NIDDK) [E] <niebylskicd@niddk.nih.gov>
Subject: RE: Interview request/chlorcyclizine pricing: BuzzFeed News

Morning Mark –

You had a bad address for Chuck so I'm adding him in with his NIDDK email.

This is actually for NIDDK to respond as we (OTT) would not feel comfortable answering questions for NIDDK on their licenses. That said, we will certainly assist NIDDK with the information we can find.

Chuck, let's chat on this tomorrow.
Deb

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Tuesday, October 25, 2016 10:15 AM
To: Kassilke, Deborah (NIH/OD) [E] <deborah.kassilke@nih.gov>; Rogers, Karen (NIH/OD) [E] <RogersK@od.nih.gov>
Cc: Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>; charles.nybeliski@nih.gov
Subject: Fwd: Interview request/chlorcyclizine pricing: BuzzFeed News

Deb and Karen:

Could you please help me follow up on this for Amanda and the press inquiry?

(b) (5)

(b) (5)

Thanks
Mark

Sent from my iPhone

Begin forwarded message:

From: "Rohrbaugh, Mark (NIH/OD) [E]"
<RohrBauM@OD.NIH.GOV>
Date: October 24, 2016 at 9:49:59 PM GMT+1
To: "Niebylski, Charles (NIH/NIDDK) [E]"
<niebylskicd@niddk.nih.gov>
Cc: "Fine, Amanda (NIH/OD) [E]" <amanda.fine@nih.gov>
**Subject: Re: Interview request/chlorcyclizine pricing:
BuzzFeed News**

Chuck:

See thread below. Could you help answer the questions about NIH licensing?

Thanks
Mark

Sent from my iPhone

Begin forwarded message:

From: "Portilla, Lili (NIH/NCATS) [E]" <portilll@mail.nih.gov>
Date: October 24, 2016 at 9:22:01 PM GMT+1
To: "Rohrbaugh, Mark (NIH/OD) [E]" <RohrBauM@OD.NIH.GOV>, "Vepa, Sury (NIH/NCATS) [E]" <sury.vcpa@nih.gov>
Subject: RE: Interview request/chlorcyclizine pricing: BuzzFeed News

Mark:

NIDDK took the lead on this as their PI (Jake Liang) was the biology lead. NCATS has a few co-inventors on the patent who did screening and med chem. The licensing for this was done by OTT specifically Kevin Chang. Chuck Nybeliski was also very involved on the NCATS side when he was part of our office. I would speak to him on this matter in his role as Director of the NIDDK TTO.

Regards,

Lili

*Lili M. Portilla, MPA
Director, Office of Strategic Alliances
National Center for Advancing
Translational Sciences, NIH
9800 Medical Center Drive, Room 3042
Rockville, MD 20850
Phone: 301-217-2589
Email: Lilip@nih.gov*

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Monday, October 24, 2016 3:51 PM
To: Driscoll, Claire (NIH/NHGRI) [E]
<cdriscol@mail.nih.gov>; Vepa, Sury (NIH/NCATS) [E] <sury.vepa@nih.gov>;
Portilla, Lili (NIH/NCATS) [E]
<portilll@mail.nih.gov>
Subject: Re: Interview
request/chlorcyclizine pricing: BuzzFeed News

Sorry Claire, meant to copy Lili

Sent from my iPhone

On Oct 24, 2016, at 8:50 PM,
Rohrbaugh, Mark (NIH/OD) [E]
<RohrBauM@OD.NIH.GOV>
wrote:



Sent from my iPhone

Begin forwarded
message:

From:
"Fine,

Amanda
(NIH/
OD)
[E]"
<amanda.fine
@nih.gov>

Date:
October 24,
2016 at
8:27:59 PM
GMT+1

To:
"Rough,
Mark
(NIH/
OD)
[E]"
<RoughBauM
@OD.NIH.GOV>

Cc:
"McBurney,
Margaret
(NIH/
OD)
[E]"
<mmc
burney@od.nih.gov>

,
"Hardisty,
Rebecca
(NIH/
OD)
[C]"
<rebecca.hardisty@

nih.gov

>

"Myles

,

Renate

(NIH/

OD)

[E]"

<myles

r@od.

.nih.gov

>

"Wojto

wicz,

Emma

(NIH/

OD)

[E]"

<emm

a.wojto

wicz@

.nih.gov

>

Subjec

t: RE:

Intervi

ew

reques

t/chlor

cyclizi

ne

pricin

g:

BuzzF

eed

News

(b) (5)

REL0000024708

(b) (5)



(b) (5)



Thanks
Mark!
Hope
you're
not
working
while
on
vacatio
n.

Amand
a

From:

Rohrbaugh,
Mark
(NIH/OD) [E]

Sent:

Monday,
October 24,
2016
3:22 PM

To:

Fine,
Amanda
(NIH/OD) [E]
<amanda.fine@nih.gov>

Cc:

McBurney,
Margaret
(NIH/OD) [E]
<mmcburney@od.nih.gov>;

Hardesty,

Rebecca
(NIH/OD) [C]
<rebecca.hardesty@nih.gov>;

Myles,
Renate
(NIH/OD) [E]
<mylesr@od.nih.gov>;

Wojtow

icz,
Emma
(NIH/O
D) [E]
<emma.wojto.wicz@nih.gov>

Subject
: Re:
Interview
w
request
/chlorc
yclizine
pricing:
BuzzFe
ed
News

I am
availab
le. Lo
oks ok
to
me. N
ot sure
why
the
email
thread
was
release
d
under
FOIA.

There
is more
one
could
say but
this is
the
basic
messag

(b) (5)



(b) (5)

Sent
from
my
iPhone

On Oct
24,
2016,
at 8:10
PM,
Fine,
Amand
a
(NIH/
OD)
[E]
<[aman
da.fine
@nih.g
ov](mailto:aman
da.fine
@nih.gov)>
wrote:

G
r
e
e
t
i
n
g
s
-

!

m
i
n
c
l
u
d
i
n
g
a
l
l
t
h
r
e
e
o
f
y
o
u
p
e
r
M
a
r
k
,
s
o
u
t
o
f
o
f
f
i
c
e
a
n
d
g
i
v
e
n
t
h

a
t
t
h
e
r
e
p
o
r
t
e
r
,
s
d
e
a
d
l
i
n
e
i
s
O
c
t
o
b
e
r
2
8
.

N
I
D
D
K
r
e
c
e
i
v
e
d
t
h
e
b

e
l
o
w
i
n
q
u
i
r
y
f
r
o
m
D
a
n
V
e
r
g
a
n
o
a
t
B
u
z
z
f
e
e
d
r
e
g
a
r
d
i
n
g
K
n
o
w
l
e
d
g
e

E
c
o
l
o
g
y
I
n
t
e
r
n
a
t
i
o
n
a
l
,
s
(
K
E
I
)
q
u
e
s
t
i
o
n
s
a
b
o
u
t
t
h
e
d
r
u
g
c
h
l
o
r

c
y
c
l
i
z
i
n
e
w
h
i
c
h
h
a
d
/
h
a
s
a
s
m
a
l
l
t
r
i
a
l
a
t
t
h
e
C
C
.
A
t
t
a
c
h
e
d
i
s
a
b
a

c
k
a
n
d
f
o
r
t
h
w
i
t
h
N
I
D
D
K
/
N
C
A
T
S
t
h
a
t
K
E
I
g
o
t
t
h
r
o
u
g
h
F
O
I
A
.
D
a
n
,
s
q

u
e
s
t
i
o
n
s
a
r
e
b
e
l
o
w

(b) (5)



(b) (5)



(b) (5)

(b) (5)

(b) (5)



(b) (5)



(b) (5)



(b) (5)



(b) (5)



(b) (5)

(b) (5)



(b) (5)

(b) (5)

(b) (5)

(b) (5)



(b) (5)

T
h
a
n
k
y
o
u
i
n
a
d
v
a

n
c
e
f
o
r
y
o
u
r
i
n
p
u
t
a
n
d
g
u
i
d
a
n
c
e
,
A
m
a
n
d
a
A
m
a
n
d
a
F
i
n
e
D
e
p
u
t
y
,
N
e
w
s
M
e

d
i
a
B
r
a
n
c
h
N
o
t
i
o
n
a
l
i
n
s
t
i
t
u
t
e
s
o
f
H
e
a
l
t
h
c
a
r
e
:
3
0
1
-
4
9
6
-
7
2
4
6
E
m
a
i
l
:
a
m
a
n
d
a
:

f
i
n
e
@
n
i
h
:
g
o
v
W
e
b
:
h
t
t
p
:
/
/
w
w
w
:
n
i
h
:
g
o
v

N
I
H
.
.
T
U
r
n
i
n
g
D
i
s
c
o
v
e
r
y
I
n
t
o
H
e

*a
l
t
h*

.....
**F
r
o
m
:
P
a
y
n
e
,
J
a
n
u
a
r
y
(
N
I
H
/
N
I
D
D
K
)
[
E
]
S
e
n
t
:
M
o
n
d
a
y
,
O
c
t
o**

b
e
r
2
4
,
2
0
1
6
2
:
5
4
P
M
T
o
:
O
C
P
L
P
r
e
s
s
T
e
a
m
<
O
C
P
L
P
r
e
s
s
T
e
a
m
@
o
d
:
n
i
h

:
g
o
v
>
;
O
D
O
C
P
L
I
n
t
e
r
v
i
e
w
s
(
N
I
H
/
O
D
O
C
P
L
)
<
O
D
O
C
P
L
!
n
t
e
r
v
i
e
w
s
@
m

a
i
i
:
n
i
h
:
g
o
v
>
C
c
:
N
I
D
D
K
N
I
D
D
K
M
E
D
I
A
(
N
I
H
/
N
I
D
D
K
)
<
n
i
d
d
k
m
e
d
i
a
@

n
i
d
d
k
:
n
i
h
:
g
o
v
>
S
u
b
j
e
c
t
:
I
n
t
e
r
v
i
e
w
r
e
q
u
e
s
t
/
c
h
l
o
r
c
y
c
l
i
z
i
n
e

p
r
i
c
i
n
g
:
B
u
z
z
F
e
e
d
N
e
w
s

H
e
l
l
o
,
N
I
D
D
K
r
e
c
e
i
v
e
d
a
n
i
n
t
e
r
v
i
e
w
r
e
q
u
e
s
t
f

r
o
m
a
B
u
z
z
f
e
e
d
r
e
p
o
r
t
e
r
a
s
k
i
n
g
a
b
o
u
t
N
I
H
i
n
v
o
l
v
e
m
e
n
t
i
n
l
i
c
e
n
s
i
n
g
a
n
d
r
u

g
p
r
i
c
i
n
g
f
o
r
c
h
l
o
r
c
y
c
l
i
z
i
n
e
.
C
h
u
c
k
N
i
e
b
y
l
s
k
i
,
d
i
r
e
c
t
o
r
o
f
N
I
D
D
K
,
s
T
e
c
h

n
o
l
o
g
y
A
d
v
a
n
c
e
m
e
n
t
O
f
f
i
c
e
,
a
s
k
e
d
t
h
a
t
I
r
e
f
e
r
t
h
i
s
r
e
q
u
e
s
t
t
o
N
I
H
O
D
a
s
i
t
i

n
v
o
l
v
e
s
N
I
H
,
s
p
o
l
i
c
y
o
n
d
r
u
g
p
r
i
c
i
n
g
.
B
e
l
o
w
i
s
t
h
e
c
o
m
p
l
e
t
e
e
m
a
i
l
e
x
c
h
a
n

g
e
l
,
v
e
h
a
d
w
i
t
h
t
h
e
r
e
p
o
r
t
e
r
,
D
a
n
V
e
r
g
a
n
o
,
a
n
d
a
t
t
a
c
h
e
d
i
s
a
P
D
F
o
f
a
n
e
m
a
i
l

c
h
a
i
n
b
e
t
w
e
e
n
N
I
H
e
m
p
l
o
y
e
e
s
t
h
a
t
t
h
e
r
e
p
o
r
t
e
r
r
e
c
e
i
v
e
d
v
i
a
a
p
u
b
l
i
c
i
n
t
e
r

e
s
t
g
r
o
u
p
c
a
l
l
e
d K
n
o
w
l
e
d
g
e
E
c
o
i
o
g
y
i
n
t
e
r
n
a
t
i
o
n
a
i
,
w
h
i
c
h
o
b
t
a
i
n
e
d
t
h
e
r
e

c
o
r
d
s
v
i
a
a
F
O
I
A
r
e
q
u
e
s
t
.
(
P
l
e
a
s
e
n
o
t
e
,
f
o
r
b
a
c
k
g
r
o
u
n
d
:
K
E
l
a
l
s
o
p
u
b
l
i
s
h
e

d
t
h
i
s
2
0
1
5
p
o
s
t
a
b
o
u
t
t
h
e
s
a
m
e
d
r
u
g
.
)

I
s
N
I
H
O
D
a
b
i
e
t
o
r
e
s
p
o
n
d
t
o
t
h
i
s
r
e
q
u

e
s
t
?

T
h
a
n
k
y
o
u
,
J
a
n
u
a
r
y
W

.
P
a
y
n
e
O
f
f
i
c
e
o
f
C
o
m
m
u
n
i
c
a
t
i
o
n
s
a
n
d
P
u
b
l
i
c
L

i
a
i
s
o
n
N
a
t
i
o
n
a
l
I
n
s
t
i
t
u
t
e
o
f
D
i
a
b
e
t
e
s
a
n
d
D
i
g
e
s
t
i
v
e
a
n
d
K
i
d
n
e
y
D
i
s
e
a
s
e
s

N
A
T
I
O
N
A
L
I
N
S
T
I
T
U
T
E
S
O
F
H
E
A
L
T
H
D
i
r
e
c
t
3
0
1
-
4
3
5
-
8
1
1
5
C
e
l
l
(b) (6)
O
f

f
i
c
e
3
0
1
-
4
9
6
-
3
5
8
3
w
w
w
:
n
i
d
d
k
:
n
i
h
:
g
o
v
N
I
H
.
.
.
T
u
r
n
i
n
g
D
i
s
c
o
v
e
r
y

I
n
t
o
H
e
a
l
t
h
®



C
e
l
e
b
r
a
t
i
o
n
o
f
S
c
i
e
n
c
e
a
t
N
I
H
:
W
a
t
c
h
h
o
w
m
e
d
i
c
a
l

r
e
s
e
a
r
c
h
s
a
v
e
s
l
i
v
e
s
a
n
d
i
m
p
r
o
v
e
s
h
e
a
l
t
h

**F
r
o
m**
:
D
a
n
V
e
r
g
a
n
o
[
m

a
i
i
t
o
:
d
a
n
:
v
e
r
g
a
n
o
@
b
u
z
z
f
e
e
d
:
c
o
m
]
S
e
n
t
:
M
o
n
d
a
y
,
O
c
t
o
b
e
r
2
4
,

2
0
1
6
1
2
:
2
9
P
M
T
o
:
P
a
y
n
e
,
J
a
n
u
a
r
y
(
N
I
H
/
N
I
D
D
K
)
[
E
]
<
i
a
n
u
a
r
y
:
p
a
y

n
e
@
n
i
h
:
g
o
v
>
S
u
b
j
e
c
t
:
R
e
:
B
u
z
z
F
e
e
d
N
e
w
s
:
p
r
e
s
s
c
o
n
t
a
c
t
/
l
i
c
e
n

s
i
n
g

J
a
n
u
a
r
y
,

T
h
a
n
k
s
f
o
r
g
e
t
t
i
n
g
b
a
c
k
t
o
m
e

-
-
T
h
e
d
r
u
g
i
s
c
h

l
o
r
c
y
c
l
i
z
i
n
e
(
l
i
n
k
t
o
l
i
c
e
n
s
e
a
n
n
c
,
t
b
e
l
o
w
)
,
a
n
d
t
h
e
p
u
b
l
i
c
i
n

t
e
r
e
s
t
g
r
o
u
p
,
K
n
o
w
l
e
d
g
e
E
c
o
l
o
g
y
I
n
t
e
r
n
a
t
i
o
n
a
l
(
w
h
i
c
h
o
f
t
e
n
l
o
o
k
s
a
t
N
I
H
l
i
c

e
n
s
e
s
)
i
s
c
o
m
p
l
a
i
n
i
n
g
t
h
a
t
i
t
s
r
e
q
u
e
s
t
f
o
r
"
r
e
a
s
o
n
a
b
l
e
p
r
i
c
i
n
g
"
r
e
q
u
i
r
e
m
e
n

t
s
i
n
t
h
e
l
i
c
e
n
s
e
w
e
r
e
b
r
u
s
h
e
d
a
s
i
d
e
t
o
t
h
e
d
e
t
r
i
m
e
n
t
o
f
t
a
x
p
a
y
e
r
s
. T
h
e
g
r
o
u
p
h

a
s
j
u
s
t
r
e
c
e
i
v
e
d
a
p
u
b
l
i
c
r
e
c
o
r
d
s
r
e
q
u
e
s
t
(
a
p
o
r
t
i
o
n
i
s
a
t
t
a
c
h
e
d
)
a
n
d
s
u
g
g
e
s
t

s
t
h
e
y
s
h
o
w
t
h
a
t
N
I
H
i
s
w
o
r
r
i
e
d
m
o
r
e
a
b
o
u
t
s
c
a
r
i
n
g
o
f
f
t
h
e
l
i
c
e
n
s
e
t
h
a
n
b
e
n
e
f
i

t
i
n
g
t
h
e
t
a
x
p
a
y
e
r
s
w
h
o
f
u
n
d
e
d
t
h
i
s
d
r
u
g
a
n
d
h
a
v
e
n
o
a
s
s
u
r
a
n
c
e
t
h
e
y
w
o
n
'
t
h
a
v
e
t

o
p
a
y
e
x
c
e
s
s
i
v
e
l
y
h
i
g
h
p
r
i
c
e
s
f
o
r
i
t
.
-
-
I
'
m
l
o
o
k
i
n
g
f
o
r
a
n
a
g
e
n
c
y
r
e
s
p
o
n
s
e
t
o

t
h
i
s
c
o
n
t
e
n
t
i
o
n
.

-
-
M
y
d
e
a
d
l
i
n
e
i
s
1
0
/
2
8
/
1
6
a
t
5
P
M
E
D
T

-
-
M
y
q
u
e
s
t
i
o
n
s
w
o
u
l
d

d
b
a
s
i
c
a
l
l
y
b
e
:

H
o
w
d
o
y
o
u
r
e
s
p
o
n
d
t
o
t
h
e
i
r
c
o
m
p
l
a
i
n
t
?

W
h
a
t
a
r
e
t
h
e
i
n
s
t
i
t
u
t

e
'
s
p
r
i
o
r
i
t
i
e
s
w
h
e
n
l
i
c
e
n
s
i
n
g
t
h
e
s
e
d
r
u
g
s
?

H
o
w
m
u
c
h
p
r
o
g
r
e
s
s
h
a
s
t
h
i
s
l
i
c
e
n

s
e
e
m
a
d
e
o
n
m
a
r
k
e
t
i
n
g
t
h
i
s
d
r
u
g
?

W
h
a
t
w
e
r
e
t
h
e
r
e
s
u
l
t
s
o
f
t
h
e
P
h
a
s
e
l
t
r
i
a
l
t
h
a

t
N
I
H
f
u
n
d
e
d
o
n
t
h
i
s
d
r
u
g
?
S
o
m
e
o
b
s
e
r
v
e
r
s
a
r
e
a
s
k
i
n
g
:
w
h
y
g
r
a
n
t
a
n

e
x
c
l
u
s
i
v
e
l
i
c
e
n
s
e
t
o
a
s
m
a
l
l
,
u
n
k
n
o
w
n
c
o
m
p
a
n
y
w
i
t
h
n
o
t
r
a
c
k
r
e

c
o
r
d
o
f
b
r
i
n
g
i
n
g
d
r
u
g
s
t
o
m
a
r
k
e
t
?

I
'
d
h
a
v
e
f
o
l
l
o
w
-
u
p
s
d
e
p
e
n
d

i
n
g
o
n
t
h
e
a
n
s
w
e
r
s
,
n
a
t
c
h
,
a
n
d
w
o
u
l
d
w
a
n
t
t
o
h
e
a
r
a
n
y
r
e
s
p
o
n
s
e
s

t
o
s
m
a
r
t
e
r
q
u
e
s
t
i
o
n
s
o
n
a
l
l
t
h
i
s
t
h
a
t
y
o
u
r
f
o
l
k
s
m
i
g
h
t
h
a
v
e
.

A
n
y
h
e
l
p
a
p
p
r
e
c
i
a
t
e
d
,

D
a
n
V
e
r
g
a
n
o
B
u
z
z
F
e
e
d
N
e
w
s
2
0
2
6
2
9
4
5
6
3

D
a
n
V
e
r
g
a
n
o

I
S
c
i
e
n
c
e
R
e
p
o
r
t
e
r
(
D
C
)
|
2
0
2
6
2
9
4
5
6
3
B
u
z
z
F
e
e
d
1
6
3
0
C
o
n
n
e
c
t
i
c
u
t
A
v
e
.
7
t
h
F

I
o
o
r
,
W
a
s
h
i
n
g
t
o
n
D
C
2
0
0
0
9

I
i
n
k
:
h
t
t
p
s
:
/
/
s
3
:
a
m
a
z
o
n
a
w
s
:
c
o
m
/
p
u
b
-
i
c
:
i
n

s
p
e
c
t
i
o
n
:
f
e
d
e
r
a
i
r
e
g
i
s
t
e
r
:
a
o
v
/
2
0
1
5
:
0
6
9
7
4
:
p
d
f

D
a
n
V
e
r
g
a
n
o
|
S
c
i
e
n

c
e
R
e
p
o
r
t
e
r
(
D
C
)
|
2
0
2
6
2
9
4
5
6
3
B
u
z
z
F
e
e
d
1
6
3
0
C
o
n
n
e
c
t
i
c
u
t
A
v
e
.
7
t
h
F
l
o
o
r
,
W

a
s
h
i
n
g
t
o
n
D
C
2
0
0
0
9

O
n
M
o
n
,
O
c
t
2
4
,
2
0
1
6
a
t
1
1
:
5
7
A
M
,
P
a
y
n
e
,
J
a
n

u
a
r
y
(
N
I
H
/
N
I
D
D
K
)
[
E
]
<
j
a
n
u
a
r
y
:
p
a
y
n
e
@
n
i
h
:
g
o
v
>
w
r
o
t
e
:

D
e
a
r

D
a
n
,

T
h
a
n
k
s
f
o
r
y
o
u
r
m
e
s
s
a
g
e
. C
a
n
y
o
u
p
l
e
a
s
e
p
r
o
v
i
d
e
m
o
r
e
i
n

f
o
r
m
a
t
i
o
n
s
o
l
c
a
n
l
o
o
k
i
n
t
o
y
o
u
r
r
e
q
u
e
s
t
?

•

W
h
a
t
i
s
t
h
e
d
r

u
g
n
a
m
e
,
a
n
d
c
a
n
y
o
u
p
l
e
a
s
e
b
r
i
e
f
l
y
d
e
s
c
r
i
b
e
t
h
e
i
s
s
u
e
t
h
a
t
h
a
s
b

e
e
n
r
a
i
s
e
d
?
A
l
s
o
,
w
h
a
t
i
s
t
h
e
n
a
m
e
o
f
t
h
e
p
u
b
l
i
c
i
n
t
e
r
e
s
t
g
r
o
u
p
?

•

W
h
a
t
i
s
y
o
u
r
h
a
r
d
d
e
a
d
l
i
n
e
?

•

C
a
n
y
o
u
p
l
e
a
s
e
p
r
o
v
i

d
e
a
f
e
w
e
x
a
m
p
l
e
s
o
f
q
u
e
s
t
i
o
n
s
y
o
u
,
d
l
i
k
e
t
o
a
s
k
?

B
e
s
t
,
J
a
n
u
a

ry W
Payne
Office of Communications and Public Liaison
National Institute

u
t
e
o
f
D
i
a
b
e
t
e
s
a
n
d
D
i
g
e
s
t
i
v
e
a
n
d
K
i
d
n
e
y
D
i
s
e
a
s
e
s

N
A
T
I
O
N
A
L
I
N
S
T
I
T
U
T
E
S
O

F
H
E
A
L
T
H

w
w
w
:
n
i
d
d
k
:
n
i
h
:
g
o
v
N
I
H
. . .
T
u
r
n
i
n
g
D
i
s
c
o
v
e
r
y
i
n
t
o
H
e
a

I
t
h
®



C
e
l
e
b
r
a
t
i
o
n
o
f
S
c
i
e
n
c
e
a
t
N
I
H
:

W
a
t
c
h
h
o
w
m
e
d
i
c
a
l
r
e
s

e
a
r
c
h
s
a
v
e
s
l
i
v
e
s
a
n
d
i
m
p
r
o
v
e
s
h
e
a
l
t
h

**F
r
o
m**
:
D
a
n
V
e
r
g
a
n
o
l
m
a

i
l
t
o
:
d
a
n
:
v
e
r
g
a
n
o
@
b
u
z
z
f
e
e
d
:
c
o
m
] **S**
e
n
t
:
M
o
n
d
a
y
,
O
c
t
o
b
e
r
2
4
,
2

0
1
6
1
1
:
2
5
A
M
T
o
:
N
I
D
D
K
N
I
D
D
K
M
E
D
I
A
(
N
I
H
/
N
I
D
D
K
)
<
n
i
d
d
k
m
e
d
i
a
@
n
i

d
d
k
:
n
i
h
:
g
o
v
>
S
u
b
j
e
c
t
:
F
w
d
:
B
u
z
z
F
e
e
d
N
e
w
s
:
p
r
e
s
s
c
o
n
t
a
c
t
/
l
i
c

e
n
s
i
n
g

K
r
y
s
t
e
n
,
s
e
m
a
i
l
r
e
s
p
o
n
d
e
r
s
u
g
g
e
s
t
e
d
I
s
c
e
n
d
t
h
i
s
n
o

t
e
t
o
t
h
i
s
c
o
n
t
a
c
t
.
I
h
a
v
e
a
l
s
o
l
e
f
t
a
p
h
o
n
e
m
e
s
s
a
g
e
w
i
t
h
t
h
e
p
r
e

s
s
o
f
f
i
c
e
.
I
a
m
l
o
o
k
i
n
g
f
o
r
c
o
m
m
e
n
t
t
h
i
s
w
e
e
k
.

M
s
.
C
a
r
r
e
r
a
,

I'm a science reporter at BuzzFeed News. I'm looking for ap-
res

s
c
o
n
t
a
c
t
a
t
N
I
D
D
K
w
h
o
c
a
n
a
d
d
r
e
s
s
a
d
r
u
g
l
i
c
e
n
s
i
n
g
i
s
s
u
e
a
t
y
o
u

r
i
n
s
t
i
t
u
t
e
.
A
p
u
b
l
i
c
i
n
t
e
r
e
s
t
g
r
o
u
p
i
s
r
a
i
s
i
n
g
q
u
e
s
t
i
o
n
s
a
b
o

u
t
o
n
c
o
f
y
o
u
r
l
i
c
e
n
s
e
s
a
n
d
I
'
d
l
i
k
e
t
o
g
e
t
a
r
e
s
p
o
n
s
e
f
r
o
m
t
h
e
i
n

S
t
i
t
u
t
e
.

T
h
a
n
k
s
f
o
r
a
n
y
h
e
l
p
.

D
a
n
V
e
r
g
a
n
o

B
u
z
z
F
e
e
d
N
e

W
S

2
0
2
/
6
2
9
-
4
5
6
3

D
a
n
V
e
r
g
a
n
o
|
S
c
i
e
n
c
e
R
e
p
o
r
t
e
r
(
D
C
)
|
2
0
2
6
2
9

4563 Buzz Feed 1630 Connecticut Ave . 7th Floor , Washington DC 20009

JANUARY PAYNE

@ National Institutes of Health

National Institutes of Health | 9000 Rockville Pike, Bethesda, MD 20892, USA
(NIH). NIH is one of the world's foremost medical research centers. An agency of the U.S. Department of Health and Human Services.



January Payne on LinkedIn



@NIH | 663K followers | 6K tweets · 3 hours ago

There's still time to submit your @NIH_LRP application! Get started on your journey to becoming a researcher. #studentdebt



Search for January Payne on Google

Did you know? January Payne is a researcher at the National Institutes of Health. She is currently working on a project related to student debt. You can find more information about her work on her LinkedIn profile.

.....

id.r

<
R
e
a
s
o
n
a
b
l
e
P
r
i
c
i
n
g
-
V
i
r
o
t
a
s
N
I
H
.
p
d
f
>

<image001.jpg>

<image001.jpg>

<image001.jpg>

<image001.jpg>



From: Rohrbaugh, Mark (NIH/OD) [E] [/O=NIH/OU=NIH/EXCHANGE/CN=OD/CN=ROHRBAUM]
Sent: 10/24/2016 8:34:35 PM
To: charles.nybeliski@nih.gov
CC: Fine, Amanda (NIH/OD) [E] [/O=NIH/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=Fineab]
Subject: Fwd: Interview request/chlorcyclizine pricing: BuzzFeed News
Attachments: image001.jpg; image001.jpg

Chuck:

See thread below. Could you help answer the questions about NIH licensing?

Thanks
Mark

Sent from my iPhone

Begin forwarded message:

From: "Portilla, Lili (NIH/NCATS) [E]" <portilll@mail.nih.gov>
Date: October 24, 2016 at 9:22:01 PM GMT+1
To: "Rohrbaugh, Mark (NIH/OD) [E]" <RohrBauM@OD.NIH.GOV>, "Vepa, Sury (NIH/NCATS) [E]" <sury.vepa@nih.gov>
Subject: RE: Interview request/chlorcyclizine pricing: BuzzFeed News

Mark:

NIDDK took the lead on this as their PI (Jake Liang) was the biology lead. NCATS has a few co-inventors on the patent who did screening and med chem. The licensing for this was done by OTT specifically Kevin Chang. Chuck Nybeliski was also very involved on the NCATS side when he was part of our office. I would speak to him on this matter in his role as Director of the NIDDK TTO.

Regards,

Lili

*Lili M. Portilla, MPA
Director, Office of Strategic Alliances
National Center for Advancing Translational Sciences, NIH
9800 Medical Center Drive, Room 3042
Rockville, MD 20850
Phone: 301-217-2589
Email: Lilip@nih.gov*

REL0000024715

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Monday, October 24, 2016 3:51 PM
To: Driscoll, Claire (NIH/NHGRI) [E] <cdriscol@mail.nih.gov>; Vepa, Sury (NIH/NCATS) [E] <sury.vepa@nih.gov>; Portilla, Lili (NIH/NCATS) [E] <portill@mail.nih.gov>
Subject: Re: Interview request/chlorcyclizine pricing: BuzzFeed News

Sorry Claire, meant to copy Lili

Sent from my iPhone

On Oct 24, 2016, at 8:50 PM, Rohrbaugh, Mark (NIH/OD) [E] <RohrBauM@OD.NIH.GOV> wrote:

(b) (5)

Sent from my iPhone

Begin forwarded message:

From: "Fine, Amanda (NIH/OD) [E]" <amanda.fine@nih.gov>
Date: October 24, 2016 at 8:27:59 PM GMT+1
To: "Rohrbaugh, Mark (NIH/OD) [E]" <RohrBauM@OD.NIH.GOV>
Cc: "McBurney, Margaret (NIH/OD) [E]" <mmcburney@od.nih.gov>, "Hardesty, Rebecca (NIH/OD) [C]" <rebecca.hardesty@nih.gov>, "Myles, Renate (NIH/OD) [E]" <mylesr@od.nih.gov>, "Wojtowicz, Emma (NIH/OD) [E]" <emma.wojtowicz@nih.gov>
Subject: RE: Interview request/chlorcyclizine pricing: BuzzFeed News

(b) (5)

Thanks Mark! Hope you're not working while on vacation.

Amanda

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Monday, October 24, 2016 3:22 PM
To: Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>

Cc: McBurney, Margaret (NIH/OD) [E] <mmcburney@od.nih.gov>; Hardesty, Rebecca (NIH/OD) [C] <rebecca.hardesty@nih.gov>; Myles, Renate (NIH/OD) [E] <mylesr@od.nih.gov>; Wojtowicz, Emma (NIH/OD) [E] <emma.wojtowicz@nih.gov>

Subject: Re: Interview request/chlorcyclizine pricing: BuzzFeed News

I am available. Looks ok to me. Not sure why the email thread was released under FOIA. There is more one could say but this is the basic message. [REDACTED] (b) (5)

(b) (5)

Sent from my iPhone

On Oct 24, 2016, at 8:10 PM, Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov> wrote:

Greetings-

I'm including all three of you per Mark's out of office and given that the reporter's deadline is October 28.

NIDDK received the below inquiry from Dan Vergano at BuzzFeed regarding Knowledge Ecology International's (KEI) questions about the drug chlorcyclizine which had/has a small trial at the CC. Attached is a back and forth with NIDDK/NCATS that KEI got through FOIA. Dan's questions are below. [REDACTED] (b) (5)

(b) (5)

Thank you in advance for your input and guidance,
Amanda

Amanda Fine
Deputy, News Media Branch
National Institutes of Health

Tel: 301-496-7246
Email: amanda.fine@nih.gov
Web: <http://www.nih.gov>

NIH . . . Turning Discovery Into Health

From: Payne, January (NIH/NIDDK) [E]
Sent: Monday, October 24, 2016 2:54 PM
To: OCPLPressTeam <OCPLPressTeam@od.nih.gov>;
ODOCPL Interviews (NIH/OD OCPL)
<ODOCPLInterviews@mail.nih.gov>
Cc: NIDDK NIDDKMEDIA (NIH/NIDDK)
<niddkmedia@niddk.nih.gov>
Subject: Interview request/chlorcyclizine pricing:
BuzzFeed News

Hello, NIDDK received an interview request from a BuzzFeed reporter asking about NIH involvement in licensing and drug pricing for chlorcyclizine. Chuck Niebyski, director of NIDDK's Technology Advancement Office, asked that I refer this request to NIH OD as it involves NIH's policy on drug pricing.

Below is the complete email exchange I've had with the reporter, Dan Vergano, and attached is a PDF of an email chain between NIH employees that the reporter received via a public interest group called Knowledge Ecology International, which obtained the records via a FOIA request. (Please note, for background: KEI also published this 2015 post about the same drug.)

Is NIH OD able to respond to this request?

Thank you,
January W. Payne
Office of Communications and Public Liaison
National Institute of Diabetes and Digestive and Kidney
Diseases
NATIONAL INSTITUTES OF HEALTH
Direct 301-435-8115
Cell (b) (6)
Office 301-496-3583
www.niddk.nih.gov

NIH...Turning Discovery Into Health®



Celebration of Science at NIH:

Watch how medical research saves lives and improves health

From: Dan Vergano
[\[mailto:dan.vergano@buzzfeed.com\]](mailto:dan.vergano@buzzfeed.com)
Sent: Monday, October 24, 2016 12:29 PM
To: Payne, January (NIH/NIDDK) [E]

REL0000024715

<january.payne@nih.gov>

Subject: Re: BuzzFeed News: press contact / licensing

January,

Thanks for getting back to me

-- The drug is chlorcyclizine (link to license annct below), and the public interest group, Knowledge Ecology International (which often looks at NIH licenses) is complaining that its request for "reasonable pricing" requirements in the license were brushed aside to the detriment of taxpayers. The group has just received a public records request (a portion is attached) and suggests they show that NIH is worried more about scaring off the licensee than benefiting the taxpayers who funded this drug and have no assurance they won't have to pay excessively high prices for it.

-- I'm looking for an agency response to this contention.

-- My deadline is 10/28/16 at 5 PM EDT

-- My questions would basically be:

How do you respond to their complaint?

What are the institute's priorities when licensing these drugs?

How much progress has this licensee made on marketing this drug?

What were the results of the Phase I trial that NIH funded on this drug?

Some observers are asking: why grant an exclusive license to a small, unknown company with no track record of bringing drugs to market?

I'd have follow-ups depending on the answers, natch, and would want to hear any responses to smarter questions on all this that your folks might have.

Any help appreciated,

Dan Vergano
BuzzFeed News
202 629 4563

Dan Vergano | Science Reporter (DC) | 202 629 4563
BuzzFeed
1630 Connecticut Ave. 7th Floor, Washington DC 20009

link: <https://s3.amazonaws.com/public-inspection.federalregister.gov/2015-06974.pdf>

Dan Vergano | Science Reporter (DC) | 202 629 4563
BuzzFeed
1630 Connecticut Ave. 7th Floor, Washington DC 20009

REL0000024715

On Mon, Oct 24, 2016 at 11:57 AM, Payne, January
(NIH/NIDDK) [E] <january.payne@nih.gov>
wrote:

Dear Dan,

Thanks for your message. Can you please provide more
information so I can look into your request?

- What is the drug name, and can you please briefly
describe the issue that has been raised? Also, what is
the name of the public interest group?
- What is your hard deadline?
- Can you please provide a few examples of
questions you'd like to ask?

Best,

January W. Payne

Office of Communications and Public Liaison
National Institute of Diabetes and Digestive and Kidney
Diseases

NATIONAL INSTITUTES OF HEALTH

www.niddk.nih.gov

NIH...Turning Discovery Into Health®



Celebration of Science at NIH:

*Watch how medical research saves lives and improves
health*

From: Dan Vergano

[mailto:dan.vergano@buzzfeed.com]

Sent: Monday, October 24, 2016 11:25 AM

To: NIDDK NIDDKMEDIA (NIH/NIDDK)

REL0000024715

<niddkmedia@niddk.nih.gov>

Subject: Fwd: BuzzFeed News: press contact / licensing

Krysten's email responder suggested I send this note to this contact. I have also left a phone message with the press office. I am looking for comment this week.

Ms. Carrera,

I'm a science reporter at BuzzFeed News. I'm looking for a press contact at NIDDK who can address a drug licensing issue at your institute. A public interest group is raising questions about one of your licenses and I'd like to get a response from the institute.

Thanks for any help,

Dan Vergano

BuzzFeed News

202/629-4563

Dan Vergano | Science Reporter (DC) | 202 629 4563
BuzzFeed
1630 Connecticut Ave. 7th Floor, Washington DC
20009

JANUARY PAYNE

@ National Institutes of Health

National Institutes of Health | 9000 Rockville Pike, Bethesda, MD 20892, USA | Official website of the Na (NIH). NIH is one of the world's foremost medical research centers. An agency of...



January Payne on LinkedIn



@NIH | 663K followers | 6K tweets - 3 hours ago

There's still time to submit your @NIH_LRP application! Get started on yours today. Deadline is Nov.1 #studentdebt




Search for January Payne on Google

Dan is using Senders. [View / edit your own Card](#)

<Reasonable Pricing - Virotas NIH .pdf>

<image001.jpg>

<image001.jpg>



From: Rohrbaugh, Mark (NIH/OD) [E] [/O=NIH/OU=NIHEXCHANGE/CN=OD/CN=ROHRBAUM]
Sent: 6/16/2017 9:28:05 PM
To: Dodson, Sara (NIH/OD) [E] [/O=NIH/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=Dodsonse]
Subject: Re: final memo to FC on royalties

Thanks. How about.

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:59 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

Sure, see the full letter below and the tracked changes Word doc attached.

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:51 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

Can you put the final showing your and Dales edits into the body of an email please? Lyric said i can get this in on Monday

Sent from my iPhone

On Jun 16, 2017, at 3:44 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

Sorry – I somehow did that in the Word doc but not in the email body. It's changed.
Anything else?

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:44 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:39 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:36 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:32 PM, Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

OK – Ignore my 4:24 reply.

(b) (5)

(b) (5)

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:29 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

Can't see the edits

(b) (5)

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:15 PM, Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

I can see OGC's and 4 comments. Do
you want me to send you all of the text
in an email and highlight OGC's
additions?

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:12 PM
To: Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov>
Subject: Re: final memo to FC on
royalties

Can you see his edits from the original?

Sent from my iPhone

On Jun 16, 2017, at 2:59 PM, Dodson,
Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

Sure, Mark. I'm taking a
look at this now.

From: Rohrbaugh, Mark
(NIH/OD) [E]
Sent: Friday, June 16,
2017 3:43 PM
To: Dodson, Sara

REL0000024757

(NIH/OD) [E]
<sara.dodson@nih.gov
>

Cc: Jorgenson, Lyric
(NIH/OD) [E]
<jorgensonla@od.nih.gov>

Subject: Fwd: final
memo to FC on
royalties

Sorry to bug you late on
Friday but could you try
and edit this today
based on my
comments. I will send
you Dale's edits
separately

Sent from my iPhone

Begin forwarded
message:

From:

"Rohrb
augh,
Mark
(NIH/O
D) [E]"

<RohrB
auM@
OD.NIH
.GOV>

Date:

June
16,
2017 at
2:28:40
PM CDT

To:

"Berkle
y, Dale
(NIH/O
D) [E]"

<Berkle
yD@OD
.NIH.G
OV>

Cc:

"Jorgen
son,
Lyric

(NIH/O
D) [E]"
<jorgen
sonla@
od.nih.
gov>,
"Hamm
ersla,
Ann
(NIH/O
D) [E]"
<hamm
erslaa
@mail.
nih.gov
>

Subject
: Re:
final
memo
to FC
on
royaltie
s

(b) (5)



(b) (5)

The
challen
ge to
edit it is
that I
am
travelin
g all
day and
can
only
work
on my

iPhone.

Sent
from
my
iPhone

On Jun
16,
2017,
at 3:09
PM,
Berkley
, Dale
(NIH/O
D) [E]
<Berkle
yD@OD
.NIH.G
OV>
wrote:

(b) (5)



(b) (5)

(b) (5)

D
a
l
e
D
.
B
e
r
k
l
e
y
.
P
h
.
D

.
,
J
.
D
.
O
f
f
i
c
e
o
f
t
h
e
G
e
n
e
r
a
l
C
o
u
n
s
e
l
,
P
H
D
,
N
I
H
B
r
a
n
c
h
B
l
d
g
.
3
1
,
R
m
.
4
7
B
e
t
h
e
s
d
a
,
M
D

2
0
8
9
2
3
0
1
-
4
9
6
-
6

0
4
3
3
0
1
-
4
0
2
-
2
5
2
8
(
F
a
x
)
T
h
i
s
m
e
s
s
a
g
e
i
s
i
n
t
e
n
d
e
d
f
o
r
t
h
e
e
x
c
l
u
s
i
v
e
u
s
e
o
f
t
h
e
r
e
c
i
p
i
e
n
t
(
s
)
n
a
m
e
d
a
b
o
v

e
.
I
t
m
a
y
c
o
n
t
a
i
n
i
n
f
o
r
m
a
t
i
o
n
t
h
a
t
i
s
P
R
O
T
E
C
T
E
D
o
r
P
R
I
V
I
L
E
G
E
D
,
a
n
d
i
t
s
h
o
u
l
d
n
o
t
b
e
d
i
s
s
e
m
i
n
a
t
e
d
,
d
i

s
t
r
i
b
u
t
e
d
,
o
r
e
o
p
i
e
d
t
o
p
e
r
s
o
n
s
n
o
t
a
u
t
h
o
r
i
z
e
d
t
o
r
e
c
e
i
v
e
s
u
c
h
i
n
f
o
r
m
a
t
i
o
n
.

F
r
o
m
:
R
o
h
r

b
a
u
g
h
,
M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
S
e
n
t
:
F
r
i
d
a
y
,
J
u
n
e
1
6
,
2
0
1
7
3
:
0
7
P
M
T
o
:

B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
<
B
e
r
k
i
e
y
D
@
O
D
:
N
I
H
:
G
O
V
>
C
c
:
J
o
r
g
e
n

s
o
n
,
L
y
r
i
c
(
N
I
H
/
O
D
)
[
E
]
<
L
o
r
g
e
n
s
o
n
i
a
@
o
d
:
n
:
h
:
g
o
v
>
;
H
a
m
m
e
r
s
I

a
,
A
n
n
(
N
I
H
/
O
D
)
[
E
]
<
h
a
m
m
e
r
s
i
a
a
@
m
a
i
l
:
n
i
h
:
g
o
v
>
S
u
b
j
e
c
t
:
R
e
:
f

i
n
a
l
m
e
m
o
r
i
a
l
t
i
e
s

(b) (5)



(b) (5)

(b) (5)

(b) (5)

(b) (5)

(b) (5)



REL0000024757

(b) (5)



(b) (5)



(b) (5)



(b) (5)

(b) (5)

(b) (5)

(b) (5)

S
e
n
t
f
r
o
m
m
y
i
p
h
o
n
e

O
n
J
u
n
1
6
,
2
0
1
7
,
a

t
1
1
:
2
6
A
M
,
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
<
B
e
r
k
l
e
y
D
@
O
D
:
N
I
H
:
G
O
V
>

w
r
o
t
e
:

A
t
t
a
c
h
e
d
a
r
e
a
f
e
w
e
d
i
t
s
a
n
d
c
o
m
m
e
n
t
s
f
o
r
y
o
u
r
c
o
n
s
i
d
e
r

a
t
i
o
n
.

B
e
s
t
,

D
a
l
e

D
a
l
e
D
.
B
e
r
k
l
e
y
,
P
h
.
D
.
J
.
D
.
O
f
f
i
c
e
o
f
t
h
e
G
e
n
e
r
a
l
C
o
u
n
s
e
l
,
P

H
D
,
N
I
H
B
r
a
n
c
h
B
l
d
g
.
3
1
,
R
m
.
4
7
B
e
t
h
e
s
d
a
,
M
D

2
0
8
9
2
3
0
1
-
4
9
6
-
6
0
4
3
3
0
1
-
4
0
2
-
2
5
2
8
(
F
a
x
)
T
h
i
s
m
e
s
s
a
g
e
i
s
i

n
t
e
n
d
e
d
f
o
r
t
h
e
e
x
c
l
u
s
i
v
e
u
s
e
o
f
t
h
e
r
e
c
i
p
i
e
n
t
(
s
)
n
a
m
e
d
a
b
o
v
e
.

I
t
m
a
y
c
o
n
t
a
i
n
i
n
f
o
r
m
a
t
i
o
n
t
h
a
t
i
s
P
R

O
T
E
C
T
E
D
o
r
P
R
I
V
I
L
E
G
E
D
,
a
n
d
i
t
s
h
o
u
l
d
n
o
t
b
e
d
i
s
s
e
m
i
n
a
t
e
d
,
d
i
s
t
r
i
b
u
t
e
d
,
o
r
c
o
p
i
e
d
t
o
p
e
r
s
o
n
s
n
o
t
a
u
t
h

o
r
i
z
e
d
t
o
r
e
c
e
i
v
e
s
u
c
h
i
n
f
o
r
m
a
t
i
o
n
.

**F
r
o
m**
:
J
o
r
g
e
n
s
o
n
,
L
y
r
i
c
(
N
I
H
/
O
D
)
[
E
]

S
e
n
t
:
F
r
i
d
a
y
,
J
u
n
e
1
6
,
2
0
1
7
1
0
:
0
7
A
M
T
o
:
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)

[
E
]
<
B
e
r
k
!
e
y
D
@
O
D
:
N
!
H
:
G
O
V
>
C
c
:
R
o
h
r
b
a
u
g
h
,
M
a
r
k
(
N
!
H
/
O
D
)
[
E
]
<

R
o
h
r
B
a
u
M
@
O
D
:
N
I
H
:
G
O
V
>
S
u
b
j
e
c
t
:
F
W
:
f
i
n
a
I
m
e
m
o
t
o
F
C
o
n
r
o
y
a
I
t
i

e
s

H
i
D
a
l
e
,

L
e
t
m
e
a
p
o
l
o
g
i
z
e
i
n
a
d
v
a
n
c
e
f
o
r
b
e
i
n
g
n
e
e
d
y
—
l
b
e
l
i

e
v
e
M
a
r
k
R
o
h
r
b
a
u
g
h
s
e
n
t
y
o
u
a
c
o
p
y
o
f
t
h
i
s
d
r
a
f
t
r
e
s
p
o
n
s
e
t
o
K
E
l
r

e
g
a
r
d
i
n
g
C
R
I
S
P
R
r
o
y
a
l
t
i
e
s
.

W
e
a
r
e
t
r
y
i
n
g
t
o
g
e
t
i
t
u
n
d
e
r
F
r
a
n
c

i
s
,
r
e
v
i
e
w
t
o
d
a
y
b
e
f
o
r
e
C
a
r
r
i
e
l
e
a
v
e
s
t
o
w
n
.

D
i
d
y
o
u
h
a
v
e
a
c
h
a
n

c
e
t
o
r
e
v
i
e
w
?

A
g
a
i
n
—
l
a
p
o
l
o
g
i
z
e
f
o
r
t
h
e
t
u
r
n
a
r
o
u
n
d
.

B
e
s
t
,

L
y
r
i
c

F
r
o
m
:
R
o
h
r
b
a
u
g
h
,
M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
S
e
n
t
:
M
o
n
d
a
y
,
M
a
y
1
5

,
2
0
1
7
3
:
1
9
P
M
T
o
:
J
o
r
g
e
n
s
o
n
,
L
y
r
i
c
(
N
I
H
/
O
D
)
[
E
]
<
i
o
r
g
e
n
s
o
n
@

Mark L. R

o
h
r
b
a
u
g
h
,
p
h
.
D
.
,
J
.
D
.
S
p
e
c
i
a
l
A
d
v
i
s
o
r
f
o
r
T
e
c
h
n
o
l
o
g
y
T
r
a
n
s
f

e
r
D
i
r
e
c
t
o
r
,
D
i
v
i
s
i
o
n
o
f
T
e
c
h
n
o
l
o
g
y
T
r
a
n
s
f
e
r
a
n
d
I
n
n
o
v
a
t
i
o
n
P

o
l
i
c
y
O
f
f
i
c
e
o
f
S
c
i
e
n
c
e
p
o
l
i
c
y
O
f
f
i
c
e
o
f
t
h
e
D
i
r
e
c
t
o
r
N
a
t
i
o
n
a
l

I
n
s
t
i
t
u
t
e
s
o
f
H
e
a
l
t
h

<
W
F
3
6
5
6
5
6
K
E
I
R
e
s
p
o
n
s
e
O
E
R
O
S
P
(
0
0
2
)
-
-

O
G
C
B
e
r
k
l
e
y
C
o
m
m
e
n
t
s
.
d
o
c
x
>

<WF365656 KEI Response OEROSP (002)--OGCBerkleyComments_MR.docx>

From: Rohrbaugh, Mark (NIH/OD) [E] [/O=NIH/OU=NIHCHANGE/CN=OD/CN=ROHRBAUM]
Sent: 6/16/2017 9:03:35 PM
To: (b) (6)
Subject: Fwd: final memo to FC on royalties
Attachments: WF365656 KEI Response OEROSP (002)--OGCBerkleyComments_MR.docx; ATT00001.htm

Sent from my iPhone

Begin forwarded message:

From: "Dodson, Sara (NIH/OD) [E]" <sara.dodson@nih.gov>
Date: June 16, 2017 at 3:59:06 PM CDT
To: "Rohrbaugh, Mark (NIH/OD) [E]" <RohrBauM@OD.NIH.GOV>
Subject: RE: final memo to FC on royalties

Sure, see the full letter below and the tracked changes Word doc attached.

(b) (5)



From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:51 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

Can you put the final showing your and Dales edits into the body of an email please? Lyric said i can get this in on Monday

Sent from my iPhone

On Jun 16, 2017, at 3:44 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

Sorry – I somehow did that in the Word doc but not in the email body. It's changed.
Anything else?

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:44 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:39 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:36 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:32 PM, Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

OK – Ignore my 4:24 reply.

(b) (5)

(b) (5)

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:29 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

Can't see the edits.

(b) (5)

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:15 PM, Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

I can see OGC's and 4 comments. Do
you want me to send you all of the text
in an email and highlight OGC's
additions?

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:12 PM
To: Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov>
Subject: Re: final memo to FC on
royalties

Can you see his edits from the original?

Sent from my iPhone

On Jun 16, 2017, at 2:59 PM, Dodson,
Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

Sure, Mark. I'm taking a
look at this now.

REL0000024759

From: Rohrbaugh, Mark
(NIH/OD) [E]
Sent: Friday, June 16,
2017 3:43 PM
To: Dodson, Sara
(NIH/OD) [E]
<sara.dodson@nih.gov>
>
Cc: Jorgenson, Lyric
(NIH/OD) [E]
<jorgensonla@od.nih.gov>
Subject: Fwd: final
memo to FC on
royalties

Sorry to bug you late on
Friday but could you try
and edit this today
based on my
comments. I will send
you Dale's edits
separately

Sent from my iPhone

Begin forwarded
message:

From:

"Rohrb
augh,
Mark
(NIH/O
D) [E]"

<[RohrB
auM@
OD.NIH
.GOV](mailto:RohrBauM@OD.NIH.GOV)>

Date:

June
16,
2017 at
2:28:40
PM CDT

To:

"Berkle
y, Dale
(NIH/O
D) [E]"

<[Berkle
yD@OD](mailto:BerkleyD@OD)>

.NIH.G

OV>

Cc:

"Jorgen

son,

Lyric

(NIH/O

D) [E]"

<jorgen

sonla@

od.nih.

gov>,

"Hamm

ersla,

Ann

(NIH/O

D) [E]"

<hamm

erslaa

@mail.

nih.gov

>

Subject

: Re:

final

memo

to FC

on

royaltie

s

(b) (5)



(b) (5)

The
challen
ge to
edit it is
that I
am
travelin

g all
day and
can
only
work
on my
iPhone.

Sent
from
my
iPhone

On Jun
16,
2017,
at 3:09
PM,
Berkley
, Dale
(NIH/O
D) [E]
<BerkleyD@OD.NIH.GOV>
wrote:

(b) (5)



(b) (5)



(b) (5)

D
a
l
e
D
.
B
e
r

k
l
e
y
,
P
h
.
D
.
,
J
.
D
.
O
f
f
i
c
e
o
f
t
h
e
G
e
n
e
r
a
l
C
o
u
n
s
e
l
,
P
H
D
,
N
I
H
B
r
a
n
c
h
B
l
d
g
.
3
1
,
R
m
.
4
7
B
e
t
h
e
s
d
a
,
M
D

2
0
8
9
2

3
0
1
-
4
9
6
-
6
0
4
3
3
0
1
-
4
0
2
-
2
5
2
8
(
F
a
x
)
T
h
i
s
m
e
s
s
a
g
e
i
s
i
n
t
e
n
d
e
d
f
o
r
t
h
e
e
x
c
l
u
s
i
v
e
u
s
e
o
f
t
h
e
r
e
c
i
p
i
e
n
t
(
s
)

n
a
m
e
d
a
b
o
v
e
.

I
t
m
a
y
c
o
n
t
a
i
n
i
n
f
o
r
m
a
t
i
o
n
t
h
a
t
i
s
P
R
O
T
E
C
T
E
D
o
r
P
R
I
V
I
L
E
G
E
D

,
a
n
d
i
t
s
h
o
u
l
d
n
o
t
b
e
d
i
s
s
e
m

i
n
a
t
e
d
,
d
i
s
t
r
i
b
u
t
e
d
,
o
r
c
o
p
i
e
d
t
o
p
e
r
s
o
n
s
n
o
t
a
u
t
h
o
r
i
z
e
d
t
o
r
e
c
e
i
v
e
s
u
c
h
i
n
f
o
r
m
a
t
i
o
n
.

**F
r
o
m**

:
R
o
h
r
b
a
u
g
h
,
M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
S
e
n
t
:
F
r
i
d
a
y
,
J
u
n
e
1
6
,
2
0
1
7
3
:
0
7

P
M
T
o
:
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
<
B
e
r
k
l
e
y
D
@
O
D
:
N
I
H
:
G
O
V
>
C
c
:
J

o r g e n s o n , L y r i c (N I H / O D) [E] < i o r g e n s o n ! a o i a : i n c : i n c > ; H a m

m
e
r
s
l
a
,
A
n
n
(
N
I
H
/
O
D
)
[
E
]
<
h
a
m
m
e
r
s
l
a
a
@
m
a
i
i
:
n
i
h
:
s
o
v
>
S
u
b
j
e
c
t

:
R
e
:
f
i
n
a
l
m
e
m
o
t
o
F
C
o
n
r
o
y
a
l
t
i
e
s

(b) (5)



(b) (5)

(b) (5)

(b) (5)

(b) (5)

(b) (5)

(b) (5)



(b) (5)

(b) (5)



(b) (5)



(b) (5)



REL0000024759

(b) (5)



(b) (5)

S
e
n
t
f
r
o
m
m
y
i
p
h
o
n
e

O
n
J
u
n
1
6
,
2

0
1
7
,
a
t
1
1
:
2
6
A
M
,
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
<
B
e
r
k
i
e
y
D
@
O
D
:
N
I
H

: G
O
V
>
w
r
o
t
e
:

A
t
t
a
c
h
e
d
a
r
e
a
f
e
w
e
d
i
t
s
a
n
d
c
o
m
m
e
n
t
s
f
o
r
y
o
u
r
c
o
n

s
i
d
e
r
a
t
i
o
n
.

B
e
s
t
.

D
a
l
e

D
a
l
e
D
.
B
e
r
k
l
e
y
.
P
h
.
D
.
J
.
D
.
O
f
f
i
c
e
o
f
t
h
e
G
e
n
e
r
a
l
C

o
u
n
s
e
l
,
P
H
D
,
N
I
H
B
r
a
n
c
h
B
l
d
g
.
3
1
,
R
m
.
4
7
B
e
t
h
e
s
d
a
,
M
D

2
0
8
9
2
3
0
1
-
4
9
6
-
6
0
4
3
3
0
1
-
4
0
2
-
2
5
2
8
(
F
a
x
)
T
h
i
s
m
e

s
s
a
g
e
i
s
i
n
t
e
n
d
e
d
f
o
r
t
h
e
e
x
c
l
u
s
i
v
e
u
s
e
o
f
t
h
e
r
e
c
i
p
i
e
n
t
(
s
)
n
a
m
e
d
a
b
o
v
e
.

I
t
m
a
y
c
o
n
t
a
i
n
i
n
f
o
r
m
a
t
i
o
n

t
h
a
t
i
s
P
R
O
T
E
C
T
E
D
o
r
P
R
I
V
I
L
E
G
E
D
,
a
n
d
i
t
s
h
o
u
l
d
n
o
t
b
e
d
i
s
s
e
m
i
n
a
t
e
d
,
d
i
s
t
r
i
b
u
t
e
d
,
o
r
c
o
p
i
e
d
t
o
p
e
r
s
o
n

s
n
o
t
a
u
t
h
o
r
i
z
e
d
t
o
r
e
c
e
i
v
e
s
s
u
e
h
i
n
f
o
r
m
a
t
i
o
n
.

**F
r
o
m
:
J
o
r
g
e
n
s
o
n
,
L
y
r
i
c
(
N
I
H
/
O**

D
)
[
E
]
S
e
n
t
:
F
r
i
d
a
y
,
J
u
n
e
1
6
,
2
0
1
7
1
0
:
0
7
A
M
T
o
:
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I

H
/
O
D
)
[
E
]
<
B
e
n
k
i
e
y
D
@
O
D
:
N
i
H
:
G
O
V
>
C
c
:
R
o
h
r
b
a
u
g
h
,
M
a
r
k
(
N
i
H
/
O
D

)
[
E
]
<
R
o
n
r
B
a
u
M
@
O
D
:
N
I
H
:
G
O
V
>
S
u
b
j
e
c
t
:
F
W
:
f
i
n
a
l
m
e
m
o
r
a
n
d
u
m
o
f
F
C
C
o
n
t
r
o
l

y
a
l
t
i
e
s

H
i
D
a
l
e
,

L
e
t
m
e
a
p
o
l
o
g
i
z
e
i
n
a
d
v
a
n
c
e
f
o
r
b
e
i
n
g
n
e
e
d
y
—

I
b
e
l
i
e
v
e
M
a
r
k
R
o
h
r
b
a
u
g
h
s
e
n
t
y
o
u
a
c
o
p
y
o
f
t
h
i
s
d
r
a
f
t
r
e
s
p
o
n
s
e
t

o
K
E
l
r
e
g
a
r
d
i
n
g
C
R
I
S
P
R
r
o
y
a
l
t
i
e
s
.

W
e
a
r
e
t
r
y
i
n
g
t
o
g
e
t
i
t
u
n
d
e
r

F
r
a
n
c
i
s
,
r
e
v
i
e
w
t
o
d
a
y
b
e
f
o
r
e
C
a
r
r
i
e
l
e
a
v
e
s
t
o
w
n
.
D
i
d
y
o
u
h
a
v
e

a
c
h
a
n
c
e
t
o
r
e
v
i
e
w
?

A
g
a
i
n
—
l
a
p
o
l
o
g
i
z
e
f
o
r
t
h
e
t
u
r
n
a
r
o
u
n
d
.

B
e

s
t
,
L
y
r
i
c

F
r
o
m
:
R
o
h
r
b
a
u
g
h
,
M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
S
e
n
t
:
M
o
n
d
a
y
,
M

a
y
1
5
,
2
0
1
7
3
:
1
9
P
M
T
o
:
J
o
r
g
e
n
s
o
n
,
L
y
r
i
c
(
N
I
H
/
O
D
)
[
E
]
<
i
o
r
e
e
n
s
o

n
a
@
o
d
:
n
h
:
g
o
v
>
S
u
b
j
e
c
t
:
f
i
n
a
l
m
e
m
o
t
o
F
C
o
n
r
o
y
a
l
t
i
e
s

M
a
r

k
L
.
R
o
h
r
b
a
u
g
h
,
P
h
.
D
.
,
J
.
D
.
S
p
e
c
i
a
l
A
d
v
i
s
o
r
f
o
r
T
e
c
h
n
o
l
o
g
y
T
r
a

n
s
f
e
r
D
i
r
e
c
t
o
r
,
D
i
v
i
s
i
o
n
o
f
T
e
c
h
n
o
l
o
g
y
T
r
a
n
s
f
e
r
a
n
d
I
n
n
o
v
a
t
i

o
n
P
o
l
i
c
y
O
f
f
i
c
e
o
f
S
c
i
e
n
c
e
P
o
l
i
c
y
O
f
f
i
c
e
o
f
t
h
e
D
i
r
e
c
t
o
r
N
a
t
i
o

n
a
l
l
n
s
t
i
t
u
t
e
s
o
f
H
e
a
l
t
h

<
W
F
3
6
5
6
5
6
K
E
I
R
e
s
p
o
n
s
e
O
E
R
O
S
P
(
0
0
2

)
-
-
O
G
C
B
e
r
k
l
e
y
C
o
m
m
e
n
t
s
.
d
o
c
x
>

From: Rohrbaugh, Mark (NIH/OD) [E] [/O=NIH/OU=NIH/EXCHANGE/CN=OD/CN=ROHRBAUM]
Sent: 6/16/2017 10:47:31 PM
To: Dodson, Sara (NIH/OD) [E] [/O=NIH/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=Dodsonse]
Subject: Re: final memo to FC on royalties

Tour of the Deep South with [REDACTED]

(b) (6)

[REDACTED] (b) (6)

Sent from my iPhone

On Jun 16, 2017, at 5:33 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

I didn't realize you were in the 'ham! [REDACTED] (b) (6) Hope you have a nice visit.

I'm attached a fresh Word doc with those changes to the last paragraph incorporated.

Have a great weekend,
Sara

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 6:19 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

Yes. Thx for your help

Greetings from Birmingham AL

Sent from my iPhone

On Jun 16, 2017, at 4:34 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

Yeah, that seems good. [REDACTED]

(b) (5)

[REDACTED] (b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 5:28 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

Thanks. How about. [REDACTED] (b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:59 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

Sure, see the full letter below and the tracked changes Word doc attached.

REL0000024761



From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:51 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

Can you put the final showing your and Dales edits into the body of an email please? Lyric said i can get this in on Monday

Sent from my iPhone

On Jun 16, 2017, at 3:44 PM, Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

Sorry – I somehow did that in the Word doc but not in the email body. It's changed. Anything else?

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:44 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

(b) (5)

A rectangular area of the email body is redacted with a solid grey fill.

Sent from my iPhone

On Jun 16, 2017, at 3:39 PM, Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

(b) (5)

A large rectangular area of the email body is redacted with a solid grey fill.

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:36 PM
To: Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:32 PM, Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

OK – Ignore my 4:24
reply.

(b) (5)

(b) (5)

From: Rohrbaugh, Mark
(NIH/OD) [E]

Sent: Friday, June 16,
2017 4:29 PM

To: Dodson, Sara
(NIH/OD) [E]
<sara.dodson@nih.gov>
>

Subject: Re: final memo
to FC on royalties

Can't see the edits.

(b)
(5)

Sent from my iPhone

On Jun 16, 2017, at
3:15 PM, Dodson, Sara
(NIH/OD) [E]
<sara.dodson@nih.gov>
> wrote:

I can
see
OGC's
and 4
comme
nts. Do
you
want
me to
send
you all
of the
text in
an
email
and
highligh
t OGC's
additio
ns?

(b) (5)

(b) (5)

From:

Rohrbaugh,
Mark
(NIH/OD) [E]

Sent:

Friday,
June
16,
2017
4:12
PM

To:

Dodson,
Sara
(NIH/OD) [E]
<sara.dodson@nih.gov>

Subject

: Re:
final
memo
to FC
on

REL0000024761

royaltie
s

Can you
see his
edits
from
the
original
?

Sent
from
my
iPhone

On Jun
16,
2017,
at 2:59
PM,
Dodson
, Sara
(NIH/O
D) [E]
<sara.dodson@nih.gov>
wrote:

S
u
r
e
,
M
a
r
k
.
I
,
m
t
a
k
i
n
g
a
l
o

o
k
a
t
t
h
i
s
n
o
w
.

F
r
o
m
:
R
o
h
r
b
a
u
g
h
,
M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
S
e
n
t
:
F
r
i
d
a

Y
,
J
u
n
e
1
6
,
2
0
1
7
3
:
4
3
P
M
T
o
:
D
o
d
s
o
n
,
S
a
r
a
(
N
I
H
/
O
D
)
[
E
]
<
S
a
r
a
:
C
o
c
o



2

>

C

J

r

e

S

n

1

r

2

14

11

I

D

1

1

January 19

Yes!

e

2

n

32

©

y
t
o
b
u
g
y
o
u
l
a
t
e
o
n
F
r
i
d
a
y
b
u
t
c
o
u
l
d
y
o
u
t
r
y
a
n
d
e
d
i
t
t
h
i
s
t
o
d
a
y
b
a

s
e
d
o
n
m
y
c
o
m
m
e
n
t
s
.
I
w
i
l
l
s
e
n
d
y
o
u
D
a
l
e
'
s
e
d
i
t
s
s
e
p
a
r
a
t
e
l
y

S
e
n

t
f
r
o
m
y
i
p
h
o
n
e

B
e
g
i
n
f
o
r
w
a
r
d
e
d
m
e
s
s
a
g
e
:

F
r
o
m
:
"
R
o
h
r
b
a
u
g
h
,

M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
"
<
R
o
h
r
B
a
u
M
@
O
D
:
N
I
H
:
G
O
V
>
D
a
t
e
:
J
u
n
e
1
6
,
2
0
1
7

a
t
2
:
2
8
:
4
0
P
M
C
D
T
T
o
:
"
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
"
<
B
e
r
k
l
e
y
D
@
O

D
:
N
I
H
:
G
O
V
>
C
c
:
"
J
o
r
g
e
n
s
o
n
,
L
y
r
i
c
(
N
I
H
/
O
D
)
[
E
]
"
<
i
o
r
g
e
n
s
o
n
:
a

0
d
n
h
g
o
v
>
,
"
H
a
m
m
e
r
s
l
a
,
A
n
n
(
N
I
H
/
O
D
)
[
E
]
"
<
h
a
m
m
e
r
s
l
a
a
@
m
a

(b) (5)

(b) (5)



(b) (5)



(b) (5)

(b) (5)



(b) (5)

(b) (5)



(b) (5)

T
h
e
c
h
a
l
l
e
n
g
e
t
o
e
d
i
t
i
t
i
s
t
h
a
t
l
a
m
t
r
a
v
e
l
i
n

g
a
l
l
d
a
y
a
n
d
c
a
n
o
n
l
y
w
o
r
k
o
n
m
y
i
P
h
o
n
e
.
S
e
n
t
f
r
o
m
m
y
i
P
h
o
n
e
O
n
J

u
n
1
6
,
2
0
1
7
,
a
t
3
:
0
9
P
M
,
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
<
B
e
r
k
i
e
y
D
@
O

D
:
N
!
H
:
G
O
V
>
w
r
o
t
e
:

(b) (5)



(b) (5)

(b) (5)

D
a
l
e
D
.
B
e
r
k
l
e
y
.
P
h
.
D
.
.
J
.
D
.
O
f

f
i
c
e
o
f
t
h
e
G
e
n
e
r
a
l
C
o
u
n
s
e
l
,
P
H
D
,
N
I
H
B
r
a
n
c
h
B
l
d
g
.
3
1
,
R
m
.
4
7
B
e
t
h
e
s
d
a
,
M
D

2
0
8
9
2
3
0
1
-
4
9
6
-
6
0
4
3
3
0
1
-
4
0

2
-
2
5
2
8
(
P
a
x
)
T
h
i
s
m
e
s
s
a
g
e
i
s
i
n
t
e
n
d
e
d
f
o
r
t
h
e
e
x
c
l
u
s
i
v
e
u
s
e
o
f
t
h
e
r
e
c
i
p
i
e
n
t
(
s
)
n
a
m
e
d
a
b
o
v
e
.

I
t
m
a
y
c

o
n
t
a
i
n
i
n
f
o
r
m
a
t
i
o
n
t
h
a
t
i
s
P
R
O
T
E
C
T
E
D
o
r
P
R
I
V
I
L
E
G
E
D
,
a
n
d
i
t
s
h
o
u
l
d
n
o
t
b
e
d
i
s
s
e
m
i
n
a
t
e
d
,
d
i
s
t
r
i
b
u
t
e
d

, o r c o p i e d t o p e r s o n s n o t a u t h o r i z e d t o r e c e i v e s u c h i n f o r m a t i o n .

F
r
o
m
:
R
o
h
r
b
a
u
g
h
,

M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
**S
e
n
t
:**
F
r
i
d
a
y
,
J
u
n
e
1
6
,
2
0
1
7
3
:
0
7
P
M
**T
o
:**
B
e
r
k
l
e

y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
<
B
e
r
t
K
e
y
w
o
r
d
s
:
N
I
H
G
l
o
b
a
l
c
o
o
r
d
i
n
a
t
i
o
n
s
,
L
y

[illegible]

N
I
H
/
O
D
)
[
E
]
<
h
a
m
m
e
r
s
i
a
a
@
m
a
i
:
:
n
h
:
p
o
v
v
S
u
b
j
e
c
t
:
R
e
:
f
i
n
a
l
m
e

m
o
t
o
F
C
o
n
r
o
y
a
l
t
i
e
s

(b) (5)



(b) (5)

(b) (5)



(b) (5)

(b) (5)



(b) (5)

(b) (5)

REL0000024761

(b) (5)



(b) (5)



(b) (5)

(b) (5)



(b) (5)



(b) (5)

S
e
n
t
f
r
o
m
m
y
i
p
h
o
n
e

O
n
J
u
n
1
6
,
2
0
1
7
,
a
t
1
1
:
2
6

A
M
,
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
<
B
e
r
k
l
e
y
D
@
O
D
:
N
I
H
:
G
O
V
>
w
r
o
t
e
:

A
t
t
a
c
h
e
d
a
r
e
a
f
e
w
e
d
i
t
s
a
n
d
c
o
m
m
e
n
t
s
f
o
r
y
o
u
r
c
o
n
s
i
d
e
r
a
t
i
o
n
.

B
e
s
t
,

D
a
l
e

D
a
l
e
D
.
B
e
r
k
l
e
y
,
P
h
.
D
.
,
J
.
D
.
O
f
f
i
c
e
o
f
t
h
e
G
e
n
e
r
a
l
C
o
u
n
s
e
l
,
P
H
D
,
N
I
H
B
r
a
n
c
h

B
l
d
g
.
3
1
,
R
m
.
4
7
B
e
t
h
e
s
d
a
,
M
D

2
0
8
9
2
3
0
1
-
4
9
6
-
6
0
4
3
3
0
1
-
4
0
2
-
2
5
2
8
(
F
a
x
)
T
h
i
s
m
e
s
s
a
g
e
i
s
i
n
t
e
n
d
e
d
f
o
r
t
h

e
e
x
c
l
u
s
i
v
e
u
s
e
o
f
t
h
e
r
e
c
i
p
i
e
n
t
(
s
)
n
a
m
e
d
a
b
o
v
e
.

I
t
m
a
y
c
o
n
t
a
i
n
i
n
f
o
r
m
a
t
i
o
n
t
h
a
t
i
s
P
R
O
T
E
C
T
E
D
o
r
P
R
I

V
I
L
E
G
E
D
,
a
n
d
i
t
s
h
o
u
l
d
n
o
t
b
e
d
i
s
s
e
m
i
n
a
t
e
d
,
d
i
s
t
r
i
b
u
t
e
d
,
o
r
c
o
p
i
e
d
t
o
p
e
r
s
o
n
s
n
o
t
a
u
t
h
o
r
i
z
e
d
t
o
r
e
c
e

i
v
e
s
u
c
h
i
n
f
o
r
m
a
t
i
o
n
.

**F
r
o
m** : J o r g e n s o n , L y r i c (N I H / O D) [E] **S
e
n
t** : F r

i
d
a
y
,
J
u
n
e
1
6
,
2
0
1
7
1
0
:
0
7
A
M
T
o
:
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
<
B
e
r
k
l
e
y

! e y D @ O D : N - H : G O V > C c : R o h r b a u g h , M a r k (N I H / O D) [E] < R O N I R B e

M
@
O
D
:
N
:
H
:
G
O
V
>
S
u
b
j
e
c
t
:
F
W
:
f
i
n
a
l
m
e
m
o
r
a
n
d
a
m
e
n
t
o
f
C
o
n
t
r
o
l
l
i
n
g
:
H
i
s
t
o
r
y
:
D
a

I
e
,
L
e
t
m
e
a
p
o
l
o
g
i
z
e
i
n
a
d
v
a
n
c
e
f
o
r
b
e
i
n
g
n
e
e
d
y
—
I
b
e
l
i
e
v
e
M
a
r
k

R
o
h
r
b
a
u
g
h
s
e
n
t
y
o
u
a
c
o
p
y
o
f
t
h
i
s
d
r
a
f
t
r
e
s
p
o
n
s
e
t
o
K
E
l
r
e
g
a
r
d
i
n

g
C
R
I
S
P
R
r
o
y
a
l
t
i
e
s
.

W
e
a
r
e
t
r
y
i
n
g
t
o
g
e
t
i
t
u
n
d
e
r
F
r
a
n
c
i
s
,
r
e
v
i

e
w
t
o
d
a
y
b
e
f
o
r
e
C
a
r
r
i
e
l
e
a
v
e
s
t
o
w
n
.

D
i
d
y
o
u
h
a
v
e
a
c
h
a
n
c
e
t
o
r
e
v

i
e
w
?

A
g
a
i
n
—
l
a
p
o
l
o
g
i
z
e
f
o
r
t
h
e
t
u
r
n
a
r
o
u
n
d
.

B
e
s
t
,

L
y
r
i
c

F
r

o
m
:
R
o
h
r
b
a
u
g
h
,
M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
S
e
n
t
:
M
o
n
d
a
y
,
M
a
y
1
5
,
2
0
1
7
3
:
1

9
P
M
T
O
:
J
o
r
g
e
n
s
o
n
,
L
y
r
i
c
(
N
I
H
/
O
D
)
[
E
]
<
i
o
r
e
s
e
m
s
o
l
u
t
i
o
n
s
@
i
o
r
e
s
e
m
s
o
l
u
t
i
o
n
s
.
c
o
m

Subject: final memoto of FCo royalties

Mark L. Rorbaugh

,
P
h
.
D
.
,
J
.
D
.
S
p
e
c
i
a
l
A
d
v
i
s
o
r
f
o
r
T
e
c
h
n
o
l
o
g
y
T
r
a
n
s
f
e
r
D
i
r
e
c
t
o

r
,
D
i
v
i
s
i
o
n
o
f
T
e
c
h
n
o
l
o
g
y
T
r
a
n
s
f
e
r
a
n
d
I
n
n
o
v
a
t
i
o
n
P
o
l
i
c
y
O
f
f
i

c
e
o
f
S
c
i
e
n
c
e
p
o
l
i
c
y
O
f
f
i
c
e
o
f
t
h
e
D
i
r
e
c
t
o
r
N
a
t
i
o
n
a
l
I
n
s
t
i
t
u
t
e

s
o
f
H
e
a
l
t
h

<
W
F
3
6
5
6
5
6
K
E
I
R
e
s
p
o
n
s
e
O
E
R
O
S
P
(
0
0
2
)
-
-
O
G
C
B
e
r
k
l
e

y
C
o
m
m
e
n
t
s
.
d
o
c
x
>

<WF365656 KEI Response OEROSP (002)--
OGCBerkleyComments_MR.docx>

<WF365656 KEI Response OEROSP (002)--OGCBerkleyComments_MR.docx>

Sure, see the full letter below and the tracked changes Word doc attached.

(b) (5)



From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:51 PM

To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>

Subject: Re: final memo to FC on royalties

Can you put the final showing your and Dales edits into the body of an email please? Lyric said i can get this in on Monday

Sent from my iPhone

On Jun 16, 2017, at 3:44 PM, Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

Sorry – I somehow did that in the Word doc but not in the email body. It's changed. Anything else?

From: Rohrbaugh, Mark (NIH/OD) [E]

Sent: Friday, June 16, 2017 4:44 PM

To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>

Subject: Re: final memo to FC on royalties

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:39 PM, Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:36 PM
To: Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

(b) (5)



Sent from my iPhone

On Jun 16, 2017, at 3:32 PM, Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

OK – Ignore my 4:24

reply. (b) (5)



(b) (5)

From: Rohrbaugh, Mark
(NIH/OD) [E]

Sent: Friday, June 16,
2017 4:29 PM

To: Dodson, Sara
(NIH/OD) [E]
<sara.dodson@nih.gov>
>

Subject: Re: final memo
to FC on royalties

Can't see the edits. (b) (5)

Sent from my iPhone

On Jun 16, 2017, at
3:15 PM, Dodson, Sara
(NIH/OD) [E]
<sara.dodson@nih.gov>
> wrote:

I can
see
OGC's
and 4
comme
nts. Do
you
want
me to
send
you all
of the
text in
an
email
and
highligh
t OGC's
additio
ns?

(b) (5)

From:
Rohrbaugh,
Mark
(NIH/OD) [E]

Sent:
Friday,
June
16,
2017
4:12
PM

To:
Dodson,
Sara
(NIH/OD) [E]
<sara.dodson@nih.gov>

Subject
: Re:
final
memo
to FC

on
royalty
s

Can you
see his
edits
from
the
original
?

Sent
from
my
iPhone

On Jun
16,
2017,
at 2:59
PM,
Dodson
, Sara
(NIH/O
D) [E]
<sara.dodson@nih.gov>
wrote:

S
u
r
e
,
M
a
r
k
.
I
,
m
t
a
k
i
n
g
a
l

o
o
k
a
t
t
h
i
s
n
o
w
.

F
r
o
m
:
R
o
h
r
b
a
u
g
h
,
M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
S
e
n
t
:
F
r
i
d

a
y
,
J
u
n
e
1
6
,
2
0
1
7
3
:
4
3
P
M
**T
o**
:
D
o
d
s
o
n
,
S
a
r
a
(
N
I
H
/
O
D
)
[
E
]
<
S
a
r
a
:
D
o
d
s
o
n

ds on @ n i n g o v > C c : J o r g e n s o n , L y r i c (N I H / O D) [E] < i o t s e n s i o n i

a
@
o
d
.
n
:
n
.
g
o
v
>
S
u
b
j
e
c
t
:
F
w
d
:
f
i
n
a
l
m
e
m
o
r
i
e
s

S
o
r

r
y
t
o
b
u
g
y
o
u
l
a
t
e
o
n
F
r
i
d
a
y
b
u
t
c
o
u
l
d
y
o
u
t
r
y
a
n
d
e
d
i
t
t
h
i
s
t
o
d
a
y
b

a
s
e
d
o
n
m
y
c
o
m
m
e
n
t
s
.
I
w
i
l
l
s
e
n
d
y
o
u
D
a
l
e
'
s
e
d
i
t
s
s
e
p
a
r
a
t
e
l
y

S
e

n
t
f
r
o
m
y
i
p
h
o
n
e

B
e
g
i
n
f
o
r
w
a
r
d
e
d
m
e
s
s
a
g
e
:

**F
r
o
m
:
"**
R
o
h
r
b
a
u
g
h

,
M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
"
<
R
O
n
r
B
a
u
M
@
O
D
:
N
I
H
:
G
O
V
>
D
a
t
e
:
J
u
n
e
1
6
,
2
0
1

7
a
t
2
:
2
8
:
4
O
P
M
C
D
T
T
o
:
"
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
"
<
B
e
r
k
i
e
v
d
@

O
D
:
N
I
H
:
G
O
V
>
C
c
:
"
J
o
r
g
e
n
s
o
n
,
L
y
r
i
c
(
N
I
H
/
O
D
)
[
E
]
"
<
I
O
I
I
B
B
e
B
S
O
B
I

(b) (5)

(b) (5)

(b) (5)

(b) (5)

(b) (5)

(b) (5)

(b) (5)

(b) (5)

T
h
e
c
h
a
l
l
e
n
g
e
t
o
e
d
i
t
i
t
i
s
t
h
a
t
l
a
m
t
r
a
v
e
l
i

n
g
a
l
l
d
a
y
a
n
d
c
a
n
o
n
l
y
w
o
r
k
o
n
m
y
i
P
h
o
n
e
.
S
e
n
t
f
r
o
m
m
y
i
P
h
o
n
e
O
n

J
u
n
1
6
,
2
0
1
7
,
a
t
3
:
0
9
P
M
,
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
<
B
e
r
k
l
e
y
D
@

O
D
:
N
I
H
:
G
O
V
>
w
r
o
t
e
:

(b) (5)



(b) (5)

(b) (5)

D
a
l
e
D
. B
e
r
k
l
e
y
, P
h
. D
. ,
J
. D
.

O
f
f
i
c
e
o
f
t
h
e
G
e
n
e
r
a
l
C
o
u
n
s
e
l
,
P
H
D
,
N
I
H
B
r
a
n
c
h
B
l
d
g
.3
1
,
R
m
.4
7
B
e
t
h
e
s
d
a
,
M
D

2
0
8
9
2
3
0
1
-
4
9
6
-
6
0
4
3
3
0
1
-

4
0
2
-
2
5
2
8
(
F
a
x
)
T
h
i
s
m
e
s
s
a
g
e
i
s
i
n
t
e
n
d
e
d
f
o
r
t
h
e
e
x
c
l
u
s
i
v
e
u
s
e
o
f
t
h
e
r
e
c
i
p
i
e
n
t
(
s
)
n
a
m
e
d
a
b
o
v
e
.

I
t
m
a

y
c
o
n
t
a
i
n
i
n
f
o
r
m
a
t
i
o
n
t
h
a
t
i
s
P
R
O
T
E
C
T
E
D
o
r
P
R
I
V
I
L
E
G
E
D
,
a
n
d
i
t
s
h
o
u
l
d
n
o
t
b
e
d
i
s
s
e
m
i
n
a
t
e
d
,
d
i
s
t
r
i
b
u
t

e
d
,
o
r
c
o
p
i
e
d
t
o
p
e
r
s
o
n
s
n
o
t
a
u
t
h
o
r
i
z
e
d
t
o
r
e
c
e
i
v
e
s
u
c
h
i
n
f
o
r
m
a
t
i
o
n
.

**F
r
o
m
:
R
o
h
r
b
a
u
g
h**

,
M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
S
e
n
t
:
F
r
i
d
a
y
,
J
u
n
e
1
6
,
2
0
1
7
3
:
0
7
P
M
T
o
:
B
e
r
k
l

e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
<
B
e
r
k
e
y
D
@
O
D
:
N
:
H
:
G
O
V
>
C
c
:
J
o
r
g
e
n
s
o
n
,
L

Y r i c (N i H / O D) [E] <

(N
I
H
/
O
D
)
[
E
]
<
h
a
m
m
e
r
s
i
a
a
a
@
m
a
i
l
:
n
h
:
B
O
V
>
**S
u
b
j
e
c
t
:
R
e
:
f
i
n
a
l
m**

e
m
o
t
o
F
C
o
n
r
o
y
a
l
t
i
e
s

(b) (5)



(b) (5)



(b) (5)

(b) (5)



(b) (5)

REL0000024763

(b) (5)

(b) (5)



(b) (5)

(b) (5)



(b) (5)



(b) (5)

(b) (5)



(b) (5)

S
e
n
t
f
r
o
m
m
y
i
P
h
o
n
e

O
n
J
u
n
1
6
,
2
0
1
7
,
a
t
1
1
:
2

6
A
M
,
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
<
B
e
r
k
l
e
y
D
@
O
D
:
N
I
H
:
G
O
V
>
W
r
o
t

e
:

A
t
t
a
c
h
e
d
a
r
e
a
f
e
w
e
d
i
t
s
a
n
d
c
o
m
m
e
n
t
s
f
o
r
y
o
u
r
c
o
n
s
i
d
e
r
a
t
i
o

n
.
B
e
s
t
,

D
a
i
e

D
a
l
e
D
.
B
e
r
k
l
e
y
,
P
h
.
D
.
,
J
.
D
.
O
f
f
i
c
e
o
f
t
h
e
G
e
n
e
r
a
l
C
o
u
n
s
e
l
,
P
H
D
,
N
I
H
B

r
a
n
c
h
B
l
d
g
.
3
1
,
R
m
.
4
7
B
e
t
h
e
s
d
a
,
M
D

2
0
8
9
2
3
0
1
-
4
9
6
-
6
0
4
3
3
0
1
-
4
0
2
-
2
5
2
8
(
F
a
x
)
T
h
i
s
m
e
s
s
a
g
e
i
s
i
n
t
e
n
d
e
d

f
o
r
t
h
e
e
x
c
l
u
s
i
v
e
u
s
e
o
f
t
h
e
r
e
c
i
p
i
e
n
t
(
s
)
n
a
m
e
d
a
b
o
v
e
.

I
t
m
a
y
c
o
n
t
a
i
n
i
n
f
o
r
m
a
t
i
o
n
t
h
a
t
i
s
P
R
O
T
E
C
T
E
D

o
r
P
R
I
V
I
L
E
G
E
D
,
a
n
d
i
t
s
h
o
u
l
d
n
o
t
b
e
d
i
s
s
e
m
i
n
a
t
e
d
,
d
i
s
t
r
i
b
u
t
e
d
,
o
r
c
o
p
i
e
d
t
o
p
e
r
s
o
n
s
n
o
t
a
u
t
h
o
r
i
z
e
d
t

o
r
e
c
e
i
v
e
s
u
c
h
i
n
f
o
r
m
a
t
i
o
n
.

**F
r
o
m** : J
o
r
g
e
n
s
o
n
, L
y
r
i
c
(N
I
H
/
O
D
) [E]
**S
e
n
t**

:
F
r
i
d
a
y
,
J
u
n
e
1
6
,
2
0
1
7
1
0
:
0
7
A
M
**T
o**
:
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[
E
]
<

B
e
r
k
l
e
y
D
@
O
D
:
N
I
H
:
G
O
V
>
C
c
:
R
o
h
r
b
a
u
g
h
,
M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
<
R
o
h
r

B
a
u
M
@
O
D
:
N
I
H
:
G
O
V
>
**S
u
b
j
e
c
t**
:
F
W
:
f
i
n
a
l
m
e
m
o
r
a
l
i
t
i
e
s

H
i
D
a
l
e
,

L
e
t
m
e
a
p
o
l
o
g
i
z
e
i
n
a
d
v
a
n
c
e
f
o
r
b
e
i
n
g
n
e
e
d
y
—
I
b
e
l
i
e
v
e

M
a
k
R
o
h
r
b
a
u
g
h
s
e
n
t
y
o
u
a
c
o
p
y
o
f
t
h
i
s
d
r
a
f
t
r
e
s
p
o
n
s
e
t
o
K
E
l
r
e
g
a

r
d
i
n
g
C
R
I
S
P
R
r
o
y
a
l
t
i
e
s
.

W
e
a
r
e
t
r
y
i
n
g
t
o
g
e
t
i
t
u
n
d
e
r
F
r
a
n
c
i
s
,

r
e
v
i
e
w
t
o
d
a
y
b
e
f
o
r
e
C
a
r
r
i
e
l
e
a
v
e
s
t
o
w
n
.

D
i
d
y
o
u
h
a
v
e
a
c
h
a
n
c
e
t

o
r
e
v
i
e
w
?

A
g
a
i
n
—
l
a
p
o
l
o
g
i
z
e
f
o
r
t
h
e
t
u
r
n
a
r
o
u
n
d
.

B
e
s
t
,

L
y
r

i
c

F
r
o
m
:
R
o
h
r
b
a
u
g
h
,
M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
S
e
n
t
:
M
o
n
d
a
y
,
M
a
y
1
5
,
2
0

173:19PMT
To: Jorgenson, Lyric (NIH/OD) [E]
<lyric.jorgenson@nih.gov>

Mark L. Rohr

b
a
u
g
h
,
p
h
. D
. ,
J
. D
. S
p
e
c
i
a
l
A
d
v
i
s
o
r
f
o
r
T
e
c
h
n
o
l
o
g
y
T
r
a
n
s
f
e
r
D
i

r
e
c
t
o
r
,
D
i
v
i
s
i
o
n
o
f
T
e
c
h
n
o
l
o
g
y
T
r
a
n
s
f
e
r
a
n
d
I
n
n
o
v
a
t
i
o
n
P
o
l
i

c
y
O
f
f
i
c
e
o
f
S
c
i
e
n
c
e
p
o
l
i
c
y
O
f
f
i
c
e
o
f
t
h
e
D
i
r
e
c
t
o
r
N
a
t
i
o
n
a
l
I
n
s

t
i
t
u
t
e
s
o
f
H
e
a
l
t
h

<
W
F
3
6
5
6
5
6
K
E
I
R
e
s
p
o
n
s
e
O
E
R
O
S
P
(
0
0
2
)
-
-
O
G
C

B
e
r
k
l
e
y
C
o
m
m
e
n
t
s
.
d
o
c
x
>

<WF365656 KEI Response OEROSP (002)--
OGCBerkleyComments_MR.docx>

From: Rohrbaugh, Mark (NIH/OD) [E] [/O=NIH/OU=NIHEXCHANGE/CN=OD/CN=ROHRBAUM]
Sent: 6/16/2017 8:35:05 PM
To: Dodson, Sara (NIH/OD) [E] [/O=NIH/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=Dodsonse]
Subject: Re: final memo to FC on royalties

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:32 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

OK – Ignore my 4:24 reply. (b) (5)

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:29 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

Can't see the edits. (b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:15 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

I can see OGC's and 4 comments. Do you want me to send you all of the text in an email and highlight OGC's additions?

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:12 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

Can you see his edits from the original?

Sent from my iPhone

On Jun 16, 2017, at 2:59 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

REL0000024772

Sure, Mark. I'm taking a look at this now.

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 3:43 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Cc: Jorgenson, Lyric (NIH/OD) [E] <jorgensonla@od.nih.gov>
Subject: Fwd: final memo to FC on royalties

Sorry to bug you late on Friday but could you try and edit this today based on my comments. I will send you Dale's edits separately

Sent from my iPhone

Begin forwarded message:

From: "Rohrbaugh, Mark (NIH/OD) [E]"
<RohrBauM@OD.NIH.GOV>
Date: June 16, 2017 at 2:28:40 PM CDT
To: "Berkley, Dale (NIH/OD) [E]"
<BerkleyD@OD.NIH.GOV>
Cc: "Jorgenson, Lyric (NIH/OD) [E]"
<jorgensonla@od.nih.gov>, "Hammersla, Ann (NIH/OD)
[E]" <hammerslaa@mail.nih.gov>
Subject: Re: final memo to FC on royalties

(b) (5)

The challenge to edit it is that I am traveling all day and can only work on my iPhone.

Sent from my iPhone

On Jun 16, 2017, at 3:09 PM, Berkley, Dale (NIH/OD) [E]
<BerkleyD@OD.NIH.GOV> wrote:

(b) (5)

Dale D. Berkley, Ph.D., J.D.
Office of the General Counsel, PHD, NIH Branch
Bldg. 31, Rm. 47
Bethesda, MD 20892
301-496-6043
301-402-2528(Fax)

REL0000024772

This message is intended for the exclusive use of the recipient(s) named above. It may contain information that is PROTECTED or PRIVILEGED, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information.

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 3:07 PM
To: Berkley, Dale (NIH/OD) [E]
<BerkleyD@OD.NIH.GOV>
Cc: Jorgenson, Lyric (NIH/OD) [E]
<jorgensonla@od.nih.gov>; Hammerslaa, Ann (NIH/OD) [E]
<hammerslaa@mail.nih.gov>
Subject: Re: final memo to FC on royalties

(b) (5)



Sent from my iPhone

On Jun 16, 2017, at 11:26 AM, Berkley, Dale (NIH/OD) [E]
<BerkleyD@OD.NIH.GOV> wrote:

Attached are a few
edits and comments for
your consideration.

Best, Dale

Dale D. Berkley, Ph.D., J.D.
Office of the General Counsel,
PHD, NIH Branch

REL0000024772

Bldg. 31, Rm. 47
Bethesda, MD 20892
301-496-6043
301-402-2528(Fax)
This message is intended for the
exclusive use of the recipient(s)
named above. It may contain
information that is PROTECTED
or PRIVILEGED, and it should not
be disseminated, distributed, or
copied to persons not authorized to
receive such information.

From: Jorgenson, Lyric
(NIH/OD) [E]
Sent: Friday, June 16,
2017 10:07 AM
To: Berkley, Dale
(NIH/OD) [E]
<BerkleyD@OD.NIH.GOV>
Cc: Rohrbaugh, Mark
(NIH/OD) [E]
<RohrBauM@OD.NIH.GOV>
Subject: FW: final
memo to FC on
royalties

Hi Dale,

Let me apologize in
advance for being
needy— I believe Mark
Rohrbaugh sent you a
copy of this draft
response to KEI
regarding CRISPR
royalties. We are trying
to get it under Francis'
review today before
Carrie leaves town. Did
you have a chance to
review?

Again – I apologize for
the turn around.

Best,

Lyric

From: Rohrbaugh, Mark
(NIH/OD) [E]
Sent: Monday, May 15,
2017 3:19 PM

REL0000024772

To: Jorgenson, Lyric
(NIH/OD) [E]
<jorgensonla@od.nih.g
ov>
Subject: final memo to
FC on royalties

Mark L. Rohrbaugh,
Ph.D., J.D.
Special Advisor for
Technology Transfer
Director, Division of
Technology Transfer
and Innovation Policy
Office of Science Policy
Office of the Director
National Institutes of
Health

<WF365656 KEI
Response OEROSP
(002)--
OGCBerkleyCommen
ts.docx>

From: Rohrbaugh, Mark (NIH/OD) [E] [/O=NIH/OU=NIHEXCHANGE/CN=OD/CN=ROHRBAUM]
Sent: 6/16/2017 8:55:35 PM
To: Dodson, Sara (NIH/OD) [E] [/O=NIH/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=Dodsonse]
Subject: Re: final memo to FC on royalties

And send the word attachments with the edits too please

Sent from my iPhone

On Jun 16, 2017, at 3:44 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

Sorry – I somehow did that in the Word doc but not in the email body. It's changed. Anything else?

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:44 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:39 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:36 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:32 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

OK – Ignore my 4:24 reply. (b) (5)

REL0000024774

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:29 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

Can't see the edits.

(b) (5)

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:15 PM, Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

I can see OGC's and 4 comments. Do you want me to
send you all of the text in an email and highlight OGC's
additions?

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:12 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

Can you see his edits from the original?

Sent from my iPhone

On Jun 16, 2017, at 2:59 PM, Dodson, Sara (NIH/OD) [E]
<sara.dodson@nih.gov> wrote:

Sure, Mark. I'm taking a look at this
now.

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 3:43 PM
To: Dodson, Sara (NIH/OD) [E]

REL0000024774

<sara.dodson@nih.gov>

Cc: Jorgenson, Lyric (NIH/OD) [E]

<jorgensonla@od.nih.gov>

Subject: Fwd: final memo to FC on royalties

Sorry to bug you late on Friday but could you try and edit this today based on my comments. I will send you Dale's edits separately

Sent from my iPhone

Begin forwarded message:

From: "Rohrbaugh, Mark (NIH/OD) [E]"
<RohrBauM@OD.NIH.GOV>

Date: June 16, 2017 at 2:28:40 PM CDT

To: "Berkley, Dale (NIH/OD) [E]"
<BerkleyD@OD.NIH.GOV>

Cc: "Jorgenson, Lyric (NIH/OD) [E]"
<jorgensonla@od.nih.gov>, "Hammersla, Ann (NIH/OD) [E]"
<hammerslaa@mail.nih.gov>

Subject: Re: final memo to FC on royalties

(b) (5)



(b) (5)

A rectangular area at the top of the page is completely redacted with a solid gray fill.

The challenge to edit it is that I am traveling all day and can only work on my iPhone.

Sent from my iPhone

On Jun 16, 2017, at 3:09 PM, Berkley, Dale (NIH/OD) [E]
<BerkleyD@OD.NIH.GOV>
V> wrote:

(b) (5)

A large rectangular area in the middle of the page is completely redacted with a solid gray fill.

Dale D.
Berkley,
Ph.D., J.D.
Office of
the General
Counsel,
PHD, NIH
Branch
Bldg. 31,
Rm. 47
Bethesda,
MD 20892

REL0000024774

301-496-
6043
301-402-
2528(Fax)
This
message is
intended for
the
exclusive
use of the
recipient(s)
named
above. It
may contain
information
that is
PROTECT
ED or
PRIVILEG
ED, and it
should not
be
disseminate
d,
distributed,
or copied to
persons not
authorized
to receive
such
information
.

From:

Rohrba
ugh,
Mark
(NIH/O
D) [E]

Sent:

Friday,
June
16,
2017
3:07
PM

To:

Berkley
, Dale
(NIH/O
D) [E]

<Berkle
yD@OD
.NIH.G
OV>

Cc:

Jorgens
on,
Lyric
(NIH/O
D) [E]

<jorgen
sonia@
od.nih.

gov>
Hamme
rsla,
Ann
(NIH/O
D) [E]
<hamm
erslaa
@mail.
nih.gov
>

Subject

: Re:
final
memo
to FC
on
royaltie
s

(b) (5)



(b) (5)



(b) (5)

Sent
from
my
iPhone

On Jun
16,
2017,
at
11:26
AM,
Berkley
, Dale
(NIH/O
D) [E]

<Berkle
yD@OD
.NIH.G
OV>
wrote:

A
t
t
a
c
h
e
d
a
r
e
a
f
e
w
w
e
d
i
t
s
a
n
d
c
o
m
m
e
n
t
s
f
o
r
y
o
u
r
c
o
n
s
i
d
e
r
a

t
i
o
n
.

B
e
s
t
,

D
a
l
e

D
a
l
e
D
.
B
e
r
k
l
e
y
.
P
h
.
D
.
J
.
D
.
O
f
f
i
c
e
o
f
t
h
e
G
e
n
e
r
a
l
C
o
u
n
s
e
l
.
P
H
D

,
N
I
H
B
r
a
n
c
h
B
l
d
g
.
3
1
,
R
m
.
4
7
B
e
t
h
e
s
d
a
,
M
D

2
0
8
9
2
3
0
1
-
4
9
6
-
6
0
4
3
3
0
1
-
4
0
2
-
2
5
2
8
(
F
a
x
)
T
h
i
s
m
e
s
s
a
g
e
i
s
i
n
t

e
n
d
e
d
f
o
r
t
h
e
e
x
c
l
u
s
i
v
e
u
s
e
o
f
t
h
e
r
e
c
i
p
i
e
n
t
(
s
)
n
a
m
e
d
a
b
o
v
e
.

I
t
m
a
y
c
o
n
t
a
i
n
i
n
f
o
r
m
a
t
i
o
n
t
h
a
t
i
s
P
R
O
T

E
C
T
E
D
o
r
P
R
I
V
I
L
E
G
E
D
,
a
n
d
i
t
s
h
o
u
l
d
n
o
t
b
e
d
i
s
s
e
m
i
n
a
t
e
d
,
d
i
s
t
r
i
b
u
t
e
d
,
o
r
c
o
p
i
e
d
t
o
p
e
r
s
o
n
s
n
o
t
a
u
t
h
o
r

i
z
e
d
t
o
r
e
c
e
i
v
e
s
u
c
h
i
n
f
o
r
m
a
t
i
o
n
.

**F
r
o
m
:
J
o
r
g
e
n
s
o
n
,
L
y
r
i
c
(
N
I
H
/
O
D
)
[
E
]
S**

e
n
t
:
F
r
i
d
a
y
,
J
u
n
e
1
6
,
2
0
1
7
1
0
:
0
7
A
M
T
o
:
B
e
r
k
l
e
y
,
D
a
l
e
(
N
I
H
/
O
D
)
[

E
]
<
B
e
r
k
I
e
Y
D
@
O
D
:
N
I
H
:
G
O
V
>
C
c
:
R
o
h
r
b
a
u
g
h
,
M
a
r
k
(
N
I
H
/
O
D
)
[
E
]
<
R

O
B
B
a
u
M
@
O
D
.
N
I
H
.
G
O
V
>
S
u
b
j
e
c
t
:
F
W
:
f
i
n
a
I
m
e
m
o
t
o
F
C
o
n
r
o
y
a
I
t
i

e
s

H
i
D
a
l
e
,

L
e
t
m
e
a
p
o
l
o
g
i
z
e
i
n
a
d
v
a
n
c
e
f
o
r
b
e
i
n
g
n
e
e
d
y
—
l
b
e
l
i

e
v
e
M
a
r
k
R
o
h
r
b
a
u
g
h
s
e
n
t
y
o
u
a
c
o
p
y
o
f
t
h
i
s
d
r
a
f
t
r
e
s
p
o
n
s
e
t
o
K
E
l
r

e
g
a
r
d
i
n
g
C
R
I
S
P
R
r
o
y
a
l
t
i
e
s
.

W
e
a
r
e
t
r
y
i
n
g
t
o
g
e
t
i
t
u
n
d
e
r
F
r
a
n
c

i
s
,
r
e
v
i
e
w
t
o
d
a
y
b
e
f
o
r
e
C
a
r
r
i
e
l
e
a
v
e
s
t
o
w
n
.

D
i
d
y
o
u
h
a
v
e
a
c
h
a
n

c
e
t
o
r
e
v
i
e
w
?

A
g
a
i
n
—
l
a
p
o
l
o
g
i
z
e
f
o
r
t
h
e
t
u
r
n
a
r
o
u
n
d
.

B
e
s
t
,

L
y
r
i
c

**F
r
o
m**

: R
o
h
r
b
a
u
g
h

, M

a
r
k

(N

I
H

/ O

D)

[E

] **S**

e

n

t :

M

o

n

d

a

y
, M
a
y
1
5

,
2
0
1
7
3
:
1
9
P
M
T
o
:
J
o
r
g
e
n
s
o
n
,
L
y
r
i
c
(
N
I
H
/
O
D
)
[
E
]
<
J
o
r
g
e
n
s
o
n
-
a
@

o
d
:
n
i
h
:
g
o
v
>
S
u
b
j
e
c
t
:
f
i
n
a
l
m
e
m
o
t
o
F
C
o
n
r
o
y
a
l
t
i
e
s

M
a
r
k
L
.
R

o
h
r
b
a
u
g
h
,
p
h
.
D
.
,
J
.
D
.
S
p
e
c
i
a
l
A
d
v
i
s
o
r
f
o
r
T
e
c
h
n
o
l
o
g
y
T
r
a
n
s
f

e
r
D
i
r
e
c
t
o
r
,
D
i
v
i
s
i
o
n
o
f
T
e
c
h
n
o
l
o
g
y
T
r
a
n
s
f
e
r
a
n
d
I
n
n
o
v
a
t
i
o
n
P

o
l
i
c
y
O
f
f
i
c
e
o
f
S
c
i
e
n
c
e
P
o
l
i
c
y
O
f
f
i
c
e
o
f
t
h
e
D
i
r
e
c
t
o
r
N
a
t
i
o
n
a
l

I
n
s
t
i
t
u
t
e
s
o
f
H
e
a
l
t
h

<
W
F
3
6
5
6
5
6
K
E
I
R
e
s
p
o
n
s
e
O
E
R
O
S
P
(
0
0
2
)
-
-

O
G
C
B
e
r
k
l
e
y
C
o
m
m
e
n
t
s
.
d
o
c
x
>

From: Rohrbaugh, Mark (NIH/OD) [E] [/O=NIH/OU=NIHEXCHANGE/CN=OD/CN=ROHRBAUM]
Sent: 6/16/2017 8:47:37 PM
To: Dodson, Sara (NIH/OD) [E] [/O=NIH/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=Dodsonse]
Subject: Re: final memo to FC on royalties

What do you think?

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:39 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:36 PM
To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>
Subject: Re: final memo to FC on royalties

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:32 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

OK – Ignore my 4:24 reply.

(b) (5)

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]
Sent: Friday, June 16, 2017 4:29 PM

REL0000024778

To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>

Subject: Re: final memo to FC on royalties

Can't see the edits.

(b) (5)

Sent from my iPhone

On Jun 16, 2017, at 3:15 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

I can see OGC's and 4 comments. Do you want me to send you all of the text in an email and highlight OGC's additions?

(b) (5)

From: Rohrbaugh, Mark (NIH/OD) [E]

Sent: Friday, June 16, 2017 4:12 PM

To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>

Subject: Re: final memo to FC on royalties

Can you see his edits from the original?

Sent from my iPhone

On Jun 16, 2017, at 2:59 PM, Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov> wrote:

Sure, Mark. I'm taking a look at this now.

From: Rohrbaugh, Mark (NIH/OD) [E]

Sent: Friday, June 16, 2017 3:43 PM

To: Dodson, Sara (NIH/OD) [E] <sara.dodson@nih.gov>

Cc: Jorgenson, Lyric (NIH/OD) [E]

<jorgensonla@od.nih.gov>

Subject: Fwd: final memo to FC on royalties

Sorry to bug you late on Friday but could you try and edit this today based on my comments. I will send you Dale's edits separately

Sent from my iPhone

Begin forwarded message:

From: "Rohrbaugh, Mark (NIH/OD) [E]"

<RohrBauM@OD.NIH.GOV>

Date: June 16, 2017 at 2:28:40 PM CDT

To: "Berkley, Dale (NIH/OD) [E]"

<BerkleyD@OD.NIH.GOV>

Cc: "Jorgenson, Lyric (NIH/OD) [E]"

<jorgensonla@od.nih.gov>,

"Hammersla, Ann (NIH/OD) [E]"

REL0000024778

<hammerslaa@mail.nih.gov>

Subject: Re: final memo to FC on royalties

(b) (5)



The challenge to edit it is that I am traveling all day and can only work on my iPhone.

Sent from my iPhone

On Jun 16, 2017, at 3:09 PM, Berkley, Dale (NIH/OD) [E]

<BerkleyD@OD.NIH.GOV> wrote:

(b) (5)



Dale D. Berkley, Ph.D., J.D.
Office of the General Counsel,
PHD, NIH Branch
Bldg. 31, Rm. 47
Bethesda, MD 20892
301-496-6043
301-402-2528(Fax)

This message is intended for the exclusive use of the recipient(s) named above. It may contain information that is PROTECTED or PRIVILEGED, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information.

From: Rohrbaugh, Mark
(NIH/OD) [E]

Sent: Friday, June 16,
2017 3:07 PM

To: Berkley, Dale
(NIH/OD) [E]

REL0000024778

<BerkleyD@OD.NIH.GOV>

V>

Cc: Jorgenson, Lyric
(NIH/OD) [E]

<jorgensonla@od.nih.gov>

; Hammersla, Ann
(NIH/OD) [E]

<hammerslaa@mail.nih.gov>

Subject: Re: final memo
to FC on royalties

(b) (5)



Sent from my iPhone

On Jun 16, 2017, at
11:26 AM, Berkley, Dale

REL0000024778

(NIH/OD) [E]
<BerkleyD@OD.NIH.GOV>
V> wrote:

Attache
d are a
few
edits
and
comme
nts for
your
conside
ration.

Best,
Dale

Dale D.
Berkley,
Ph.D., J.D.
Office of
the General
Counsel,
PHD, NIH
Branch
Bldg. 31,
Rm. 47
Bethesda,
MD 20892
301-496-
6043
301-402-
2528(Fax)
This
message is
intended for
the
exclusive
use of the
recipient(s)
named
above. It
may contain
information
that is
PROTECT
ED or
PRIVILEG
ED, and it
should not
be
disseminate
d,
distributed,
or copied to
persons not
authorized
to receive
such
information
.

From:
Jorgens
on,
Lyric

(NIH/O

D) [E]

Sent:

Friday,

June

16,

2017

10:07

AM

To:

Berkley

, Dale

(NIH/O

D) [E]

<Berkle

yD@OD

.NIH.G

OV>

Cc:

Rohrba

ugh,

Mark

(NIH/O

D) [E]

<RohrB

auM@

OD.NIH

.GOV>

Subject

: FW:

final

memo

to FC

on

royaltie

s

Hi Dale,

Let me

apologi

ze in

advanc

e for

being

needy—

I

believe

Mark

Rohrba

ugh

sent

you a

copy of
this
draft
response
to KEI
regarding
CRISPR
royalties.
We
are
trying
to get it
under
Francis'
review
today
before
Carrie
leaves
town.
Did you
have a
chance
to
review?

Again –
I
apologize
for
the
turn
around.

Best,

Lyric

From:
Rohrbach,
Mark
(NIH/OD) [E]
Sent:
Monday, May
15,
2017
3:19
PM
To:

Jorgens
on,
Lyric
(NIH/O
D) [E]
<jorgen
sonia@
od.nih.
gov>

Subject
: final
memo
to FC
on
royaltie
s

Mark L.
Rohrba
ugh,
Ph.D.,
J.D.
Special
Advisor
for
Technol
ogy
Transfe
r
Directo
r,
Division
of
Technol
ogy
Transfe
r and
Innovat
ion
Policy
Office
of
Science
Policy
Office
of the
Directo
r
Nationa
l
Institut

es of
Health

<WF3
65656
KEI
Respon
se
OERO
SP
(002)--
OGCB
erkley
Comm
ents.do
cx>